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ABSTRACT 
 
Many human disorders are associated with the malfunction of smooth muscle 
tissue, or are related to the capabilities of its proper function—asthma, glaucoma, renal 
inefficiency, hypertension, and cardiovascular disease.  Dysfunctional proteins are 
frequently implicated as the source of such disorders.  As the second highest cause of 
death in the United States, the epidemic of cardiovascular disease makes the study of 
smooth muscle of utmost concern.   
The capabilities of proteomics and mass spectrometry allow the entire proteome 
complement of a cell or tissue type to be analyzed at once.  This investigation employs 
such techniques in an effort to better understand the mechanisms of signal transduction 
for the contraction of smooth muscle tissue.   The differential phosphorylation of proteins 
between resting and contracted tissue was targeted, specifically, because phosphorylation 
is the primary means of communication and activity modification of proteins. Much of 
what is known about the regulation of signal transduction in smooth muscle contraction is 
conducted through the activation of myosin light chain kinase (MLCK) and/or myosin 
light chain phosphatase (MLCP).   
Protocols of analysis using phosphoproteomic techniques and MALDI-TOF MS 
were developed for the purposes of this investigation.  The localization of the more 
abundant proteins actin, myosin heavy chain (MHC), and tropomyosin was determined 
on a 2D gel.  Tropomyosin was found to be phosphorylated in phorbol-contracted tissue, 
indicating that this protein may play a larger role in contractile regulation than originally 
thought.  The function of such thin-filament associated proteins should be investigated 
more thoroughly.   A thorough understanding of contraction in normal tissue will provide 
the base for which dysfunctions can be compared.  Continued improvements in 
methodology will aid the advancement of this research.   
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INTRODUCTION 
 
 
 
Smooth Muscle 
 
 Smooth muscle (SM) tissue consists of the involuntary muscles found in the lining of 
most hollow organs, including blood vessels, and functions to produce and regulate tension and 
mechanical processes.  The primary function of SM is contraction—tension development and 
maintenance.  Generated force is used to regulate such processes as blood flow/circulation, 
movement through the gastrointestinal (GI)/urogenital (UI) tracts, retinal function (light 
reactions, pressure), and laboral uterine contractions (Abdel-Latif, 2001).  SM tissue can be 
classified into six different types:  vascular, respiratory, urinary, reproductive, gastrointestinal, 
and ocular. 
 Many disorders are associated with either the malfunction of SM tissue, or are related to 
the capabilities of its proper function.  These include cardiovascular disease, hypertension (high 
blood pressure), glaucoma, asthma, renal inefficiency, restenosis, atherosclerosis, and cerebral 
vasospasm.  In particular, overconstriction, or blockage of blood vessels, can cause hypertension 
and heart disease. 
 According to research conducted by the World Health Organization (WHO), 
approximately 16.6 million people around the world die a year from cardiovascular-associated 
disorders with approximately 600 million people at high risk for heart attack, stroke, and/or 
cardiac failure (WHO, 2002).  What’s more these numbers are growing (WHO 2002).  To add to 
the weight of this problem, the age of monitored patients is decreasing.  The average age of 
afflicted patients used to be in the 70s, but has grown to include those in their 30s or 40s 
(Nurseweek, 2003). 
 An estimated $352 billion a year will be spent in America for the treatment and disability 
coverage of heart disease.  As the leading cause of death in many countries, including the United 
States, risk factors include: hypertension, high cholesterol, obesity, diabetes, heredity, tobacco 
use, poor diet, increasing age, physical inactivity, and excess alcohol intake (AHA, 2003). 
 Treatment and prevention of this epidemic begins with an understanding of normal SM 
function—both its mechanical and biochemical properties.  Devising how signaling pathways are 
 1
altered during the state of disease would be the next step to develop treatments for a disorder.  
For example, one of the primary treatments for patients enduring overconstriction of blood 
vessels or airways is to treat them with a vasodilator, an agonist that signals SM tissue to relax, 
such as nitroglycerine which produces nitric oxide (NO).  
 Smooth muscle can be characterized as either tonic or phasic (Somlyo 1968, 1990).  
Phasic SM demonstrates activation of contraction via the production of action potentials, and 
develops faster shortening and tension development (Somlyo 1968, 1993, 1994; Johansson 
1980).  Tonic SM exhibits graded polarization, or slower waves of Ca2+ influx (Fuglsang 1993; 
Somlyo 1993; Prosser 1992).  
 
 
Smooth Vs. Skeletal: Similarities 
 
Composition 
 
 Both smooth and skeletal muscle have many of the same proteins related to contractile 
activities and/or signal transduction, although they have different isoforms. (see appendix III for 
protein info.)  Such proteins include:  actin, myosin, MgATPase, calmodulin (CaM), voltage-
dependent anion channels, and myosin light chain kinase (MLCK)—though the structure of this 
protein in the two muscles is very different (Hartshorne 1987).  Actin is made up of G-actin 
monomers that compose the thin filaments to make F-actin.  Myosin is a hexameric protein.  The 
six monomers that make up myosin consist of two heavy chains (MHC), two essential light chain 
monomers (MLCessential) and two myosin regulatory light chains (MLC-20) (See Appendix IV). 
 
Regulation of Contraction 
 
Both types of muscle contractions are regulated by depolarization states of the plasma 
membrane ( PM) and cytosolic concentrations of calcium ([Ca2+]), referred to as 
electromechanical coupling.  Electrical depolarization of the membrane from a resting potential 
of -70 to -40 mV (depending on the cell type) to a more positive potential causes the opening of 
voltage-gated calcium (Ca2+) channels in the plasma membrane (PM) and the sarcoplasmic 
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reticulum (SR) leading to increased levels of cytosolic Ca2+  (Somlyo 1989; Johansson 1980).  
Contraction occurs with a change to a more positive membrane potential (depolarization), 
relaxation occurs when the potential switches back to a more negative potential (repolarization), 
(Filo 1965; Somlyo 1998). 
  
Mechanism of Contraction 
 
Both muscles use the same actomyosin molecular motor (MgATPase) to facilitate 
mechanical contraction via the familiar, well-researched sliding filament mechanism.  Briefly, a 
phosphorylated myosin regulatory light chain (MLC-20) from myosin thick filaments enables the 
MgATPase motorized myosin head to walk along the thin filaments of actin (F-actin), shortening 
and contracting muscle fibers (Figures 1 and 2, below).  
 
 
Figure 1:  Illustration of the mechanism of the sliding filament model in a repeated 5 step operation.  1) Myosin 
heads are bound to actin filaments at the myosin binding site.  2) ATP binds to the regulatory light chain of myosin 
(MLC-20). The myosin head dissociates.  3) Hydrolysis of ATP causes a conformational change in the myosin head 
into a “cocked” formation.  4) The myosin head binds the actin filament again. 5) ADP is released, and the myosin 
head pulls the myosin filament forward in the “power stroke”.  
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Figure 2:  Model of the sliding filament mechanism of contraction, in which activated MgATPase myosin heads 
walk along actin filaments to shorten and contract fiber lengths.  
 
These actomyosin interactions are called cross-bridges.  Similarity in the behavior of force-
velocity relationships in response to changes in muscle length and tension development support 
this theory of analogous contraction (Hibberd 1989; Somlyo 1988, Horiutu 1989; Arner 1987; 
Fuglsang 1993). 
  
Smooth Vs. Skeletal: Differences 
 
Ultrastructure and Composition 
 
Though the two types of muscle fibers share similar components and the same general 
mechanism, they differ in their ultrastructural design, and consequently, many of their 
mechanical properties. Skeletal muscle fibers are arranged in a striated organization of stacked 
filaments in repeating units called sarcomeres. Smooth muscle fibers exist as ordered arrays of 
crossed filaments (Figures 3 and 4, below).  SM also has a greater ratio of actin to myosin, with a 
much lower level of myosin than skeletal muscle.  The abundances of actin and tropomyosin are 
consistent with skeletal muscle.  Actin filaments are attached to dense bodies containing α-
actinin, assumed to be analogous to the Z-discs in skeletal muscle.   
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Figure 3:  Illustration of the arrangement or skeletal muscle fibers—repeating units of the sarcomere.  
 
 
 
Figure 4:  Arrangement of smooth muscle fibers in ordered arrays of crossed filaments.  
  
Mechanism of Contraction  
 
The mechanism by which increasing [Ca2+] induces contraction in skeletal and smooth 
muscle differs, as well.  In skeletal muscle, Ca2+  binds to troponin C (TnC)—a regulatory protein 
associated with actin through tropomyosin (Tm)—that causes a conformational change which 
moves tropomyosin from blocking the actomyosin interaction (Ebashi 1991).  
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 Figure 5:  Illustration of the mechanism by which induces contraction in skeletal muscle.  Troponin C  
binds Ca2+ and causes a conformational change in Tropomyosin, which moves from inhibiting myosin from the 
actomyosin binding site. 
 
 SM does not have troponin proteins.  It has calponin and caldesmon associated with its 
thin filaments.  In SM, Ca2+ binds to Calmodulin (CaM), and this complex then binds myosin 
light chain kinase (MLCK).  The Ca-CaM-MLCK complex then phosphorylates MLC-20 at 
serine 19, allowing contraction (Hartshorne 1987; Sweeney 1994).  However, it has been 
proposed that thin-filament-associated proteins in SM aid in regulation of contraction when 
phosphorylated by a kinase (Adam 1992; Sobue 1991; Marsten 1991; Winder 1993). 
 
Regulation of Contraction 
 
 The two types of muscle also differ in the stimulus and regulation of 
contraction/relaxation.  Skeletal muscle cell depolarization of the membrane is activated by 
nerve impulses that release acetylcholine and induce subsequent depolarization.  Smooth muscle 
contraction is controlled not only by depolarization, but also by many signaling molecules and 
cross-talking pathways, called pharmacochemical coupling.  Table 1 lists some common agonists 
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of contraction and relaxation.  Contraction may be regulated by calcium-independent 
mechanisms, where constant [Ca2+] levels are associated with changes in the level of MLC-20 
phosphorylation and/or tension.  This phenomenon is called calcium 
sensitization/desensitization, depending on whether the contractile response becomes more or 
less sensitive to [Ca2+].   
 
 
                          Agonists of Contraction                Stimulants of Relaxation 
High Cytocolic Ca2+ Low cytosolic Ca2+ 
High Extracelluar K+ (KCl) Hyerpolarization of membrane 
Depolarization of membrane STICs 
STOCs Dantrolene 
Angiotension Kaurenoic acid 
Norepenephrine Adrenomedullin 
Catacholamines Prostaglandin E2 (EP2) 
Histamine Calcitonin gene-related peptide 
Triethanolamine (TEA) β-Adrenergic receptor agonist 
Polycations 
         -spermin, neomycin, polylysine 
Inhibitors of CaM 
        -trifluoroperazine, mastoparan, W13 
Endothelin (ET) Elevators of cAMP/cGMP 
Bradykinin Forskolin 
Phorbol esters Isoproterenol 
Prostaglandin F2 (PGF2) Prazosin 
Muscarine Rnd1 
Oxotremorin Y-27632 (ROK inhibitor) 
Serotonin ERK inhibitors 
5-hydroxytryptamine Vasonatrin peptide 
Interleukin-1 Some tyrosine kinase inhibitors 
Vasopressin IBMX 
Thrombin NO 
carbachol Atrial natriuretic peptide 
Methylene blue ERF 
Superoxide EDHF (hyperpolarizing factor) 
Oxytocin  
 
Table 1:  Common agonists and inhibitors of contraction and relaxation in smooth muscle tissue. 
 
 
Regulatory proteins demonstrate changes in function independent of cytosolic [Ca2+].  Such 
regulation often occurs when contraction is stimulated by agonist-induced receptor activated 
contraction in what is called pharamacomechanical coupling.  Such sensitization/desensitization 
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is manifested primarily in the regulation of MLC-20 phosphorylation, activity of MLCK, and/or 
activity of myosin light chain phosphatase (MLCP), as will be discussed.   
 
Mechanical Properties 
 
 The differences in structure are accompanied by unique mechanical properties of SM 
tissue.  For example, smooth muscle demonstrates maximum force generation at a specific given 
length.  Yet, it operates at a length far below this optimum.  When SM is stretched beyond this 
length, an increasing interference of passive force—that not generated by the active muscle—
causes stress relaxation and hysteresis, which poses as a problem for those trying to measure its 
mechanical features, and is probably why SM does not operate in this range.  Smooth muscle 
also demonstrates much greater series elasticity, which is the length to which the tissue can be 
stretched while maintaining its mechanical properties (Van Magstrigt 2002). 
Smooth muscle tissue can demonstrate a sustained state of contraction, called tonic 
contraction, as well as phasic contraction.  Skeletal muscles operate only as rapid phasic 
contractions (brief, intense contractions).  However, skeletal muscle has a faster maximum 
shortening velocity and MgATPase activity (Somlyo 1988; Horiutu 1989).   
The work of Wright et al. at the Marshall University School of Medicine (MUSOM) has 
demonstrated the ability of SM to generate more force per unit of cross-sectional area than 
skeletal muscle (Wright, 2003). Smooth muscle also demonstrates an increased number of cross-
bridge attachments and is slow to redevelop force after quick release of tension (Somlyo 1967).  
Yet, SM shows improved energy metabolism, with the ability to use less ATP to maintain force 
(Hartshorne 1987; Siegman 1980; Rembold 1993).   
Unique to SM is a phenomenon known as latch.  There is no direct correlation between 
the level of MLC-20 phosphorylation and force (Pfitzer 2001), and this is probably due to 
maintenance of cross-bridge association without phosphorylation.  This characteristic is known 
as latch (Huxley 1957).  Such differences in mechanical properties are undoubtedly accompanied 
by differences in the biochemistry of involved proteins which perform and regulate contractility 
functions. 
 
SM Heterogeneity 
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  A striking lone aspect of SM tissue lies in its inherent heterogeneity.  The same agonist 
can elicit different responses in different types of SM tissue, or even in different segments of the 
same vessel.  The same pharamacochemical agent can cause contraction in one tissue, and 
relaxation in another (Bulbring 1993).  Agonists can be coupled to Ca2+-dependent or Ca2+-
independent contraction, and many agonists/relaxing agents are coupled to G-protein  
receptors.  The efficiency with which an agonist induces a response can also differ greatly 
(Somlyo 1994). 
 
Smooth Muscle Mechanics 
  
 The mechanical properties of SM are characterized by force/tension development of 
tissue as a function of tissue length and time.  Such properties are referred by measuring the 
velocity of change in tension when tissue is shortened or stretched.  Properties are investigated 
from two perspectives 1) analysis of physiological muscle properties to generate normal force-
velocity curves, and 2) analysis of properties outside the physiological range, which demonstrate 
series elasticity (Van Magstrigt 2002).   
Two methods exist for producing force-velocity curves.  One can either add load 
(weights) to active muscle and record length changes, or apply shortening velocities to the 
muscle to reach a given length, followed by recording of changes in force.  However, activities 
should be repeated to eliminate measurements of passive force (Van Mastrigt 1985). Factors that 
affect mechanical properties include muscle size, number of cross-bridges, orientation of cross-
bridges to each other (series, parallel), and duration of exposure to stimuli (Van Mastrigt 2002). 
The force-velocity relationship in SM fits the parabolic curve generated by the Hill 
equation (Hill 1985), except when stretched, where the curve becomes more linear.  Passive 
force becomes a large influence on measurements starting from the point of optimal force 
development and probably causes a large amount of this linearity (Uvelius 1977, 1979, 1980; 
Moriya 1985; Stephens 1985; Van Koeveringe 1997).  No apparent explanation exists for the 
effects of stretching on shortening velocities, and conflicting supporting data is reflected in the 
literature (Uvelius 1977; Malmqvist 1991; Minekus 2001; Van Mastrigt 1999).  
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Signal Transduction Pathways 
 
 The SM cell is a complex structure with many points of regulation.  Several signaling 
pathways within the SM cell have been elucidated in the past 30 years.  The following 
subsections include diagrams of the complex pathways, which will be discussed briefly within 
the text.  Figure 6, below, defines the symbols used in the diagrams of signal transduction 
pathways. 
 
 
Figure 6:  Legend defining the symbols used in the diagrams of signal transduction pathways in SM cells. 
 
 
Ca2+ Influx  
 Calcium (Ca2+) influx occurs through Ca2+ channels in the plasma membrane (PM) and 
the sarcoplasmic reticulum (SR).  The rate of influx depends on the kinetic properties of the ion 
channels (Kotlikoff 1999).  Depolarization of the PM from resting potential to a more positive 
potential—from -70 to -40 mV, depending on cell type— causes opening of voltage-gated ion 
channels, and subsequent contraction.  Repolarization of the cell membrane to a more negative 
potential results in relaxation (Somlyo 1989; Johansson 1980).   
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Ca2+ Flux in SM 
 
 
Figure 7:  Diagram illustrating the flux of calcium ions within the SM cell. 
 
In the cytoplasm, calcium-binding buffer proteins bind the influx of excess Ca2+ 
(Kargacin 1994). It has now been proposed that the local distribution of buffers and contractile-
regulating proteins near the site of influx governs the nature and the extent of the response (Iino 
1989).  An action potential in phasic SM exceeds the buffering capacity of the cell and the signal 
to contract is initiated (Bond 1984). The level of excess [Ca2+] depends on the extent of 
depolarization and the concentration of surrounding buffers.  
Voltage-gated ion channels are activated by depolarization, and are specific for calcium.  
Ligand-gated ion channels are non selective and may function to activate voltage-dependent 
channels (Somlyo 1991; Somlyo 1994).  The properties of ion channels vary between smooth 
muscle cell type, as well (Kuriyama 1992; McDonald 1994).  To facilitate relaxation, most of the 
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Ca2+ is removed from the cytosol by the Ca2+-pump of the SR, though some is removed by the 
Ca2+-ATPase pump and a Na+/ Ca2+ exchanger pump in the PM (Bond 1984; Carafoli 1993; 
Juhaszova 1993; Aaronson 1981). 
 Recently, the potent effects of Ca2+ sparks on membrane potential have been studied 
(Nelson 1995).  These sparks are local, short-lived releases of Ca2+ through Ryanodine receptors 
(RyaR)—at least ten (ZhuGe 2000)—in the SR, causing a high local [Ca2+].  The effect depends 
on the local environment of the spark.  The excess local Ca2+ can 1) activate IP3 receptors to 
generate a larger “wave” of Ca2+ due to faster diffusion of IP3 (Jaggar 2000; Ganitkevich 2002), 
or 2) activate Ca2+-activated potassium (K+) channels (BK channels), causing hyperpolarization 
and relaxation—STOCs (spontaneous transient outward currents) (Bolton 1996), or 3) may 
induce Ca2+-activated chloride (Cl-) ion channels and cause depolarization and contraction—
STICs (spontaneous transient inward currents) (ZhuGe 1998).  Several messengers, in known 
signaling pathways, cause increases or decreases in Ca2+ spark frequency (Porter 1998; Wellman 
2001; Bonev 1997; Jaggar 2000). 
 
Calcium Sensitization/Desensitization  
 
 As referred to before, calcium sensitization/desensitization is mediated mostly through 
changes in the function of MLC-20, MLCK, MLCP, or even the actomyosin MgATPase itself.  
The extent of MLC-20 phosphorylation depends on the relative activation/deactivation of 
MLCK/MLCP, which are the main targets of regulatory proteins.  However, changes in 
contraction can occur without changes in MLC-20 phosphorylation.  It has been suggested that 
thin-filament-associated proteins—caldesmon, calponin—mediate cross-bridge attachments in 
smooth muscle as they do in skeletal muscle, possibly when phosphorylated by mitogen-
activated protein kinase (MAPK) (Arner 1999; Adam 1992; Sobue 1991; Marston 1991; Winder 
1993).  It has also been found that small heat shock proteins may directly inhibit the MgATPase, 
when they are phosphorylated by PKA or PKG (Barany 1996; Beal 1997; Rembold 2000; 
Brophy 1999). 
Phosphorylation has also been shown to decline without loss of tension (Kamm 1985; 
Fischer 1989; Sward 2000), and it has been suggested that MLC-20 is actually dephosphorylated 
while cross-bridges are still intact or are slowly detached (Murphy 1994). This is an example of 
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the latch state, where a low level of MLC-20 phosphorylation is associated with a high 
maintenance of force and low corresponding expenditure of ATP (Huxley 1957).  Another 
suggestion allows that non-phosphorylated cross-bridges are attached with the assistance of 
calponin and caldesmon (CaD) (Arner 1987; Khromov 1995; Somlyo 1988; Vyas 1992; Albrecht 
1997; Matsui 1996) or that of already attached cross-bridges (Somlyo 1988; Somlyo 1990).  In 
addition, relaxation has been shown to occur while increased numbers of MLC-20 are still 
phosphorylated (Barany 1993; Katoch 1997; McDaniel 1992; Tansey 1990).  The relation 
between the level of force and degree of phosphorylation may also depend on the type of agonist 
used (Suematsu 1991).  
 Many kinases other than MLCK have been discovered to phosphorylate MLC-20, 
including Rho-associated kinase, which phosphorylates MLC-20 in the peripheral region of the 
cell (ROK) (Amano 1996; Miyazaki 2002), Integrin-linked kinase (Deng 2001), ZIP kinase 
(Niiro 2001), MAPK (Takahashi 1998; Dessy 1998; Ohmichi 1997; Velarde 1999; Yousufzai 
2000), Ca2+-Calmodulin Kinase II (CaM KII) (Pfitzer 1989), Protein Kinase C (PKC) (Lee 1999, 
Katoch 1999), some unidentified staurosporine-sensitive kinases (Kureishi 1999; Iizuka 1999; 
Weber 1999), and possibly some other unidentified kinases (Trinkle-Mulcahy 1995; Ichikawa 
1996; Hartshorne 1998).  The potency or relative importance of these kinases is not yet fully 
understood, and can vary with the type of agonist used (Ganitkevich 2002). 
 
 
 
 
 
 
 
Contraction Pathways in SM 
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Figure 8:  Diagram illustrating the signal transduction pathways involved in contraction of the SM cell. 
 
 
 
 Activation of MLCK by complexation with Ca-CaM causes it to phosphorylate MLC-20 
and induce contraction.  The affinity of MLCK for Ca-CaM can be decreased if it is 
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phosphorylated.  It has been shown to be phosphorylated by p42/p44 MAPK (Klemke 1997), 
p21 activated protein kinase (PAK) (Sanders 1999), Cam KII (Tansey 1992), and cAMP-
dependent protein kinase (PKA), which causes 10-fold decrease in Ca2+-sensitivity (Conti 1981; 
De Lanerolle 1984; Adelstein 1982), .  It has also been found that the myosin binding region of 
MLCK can bind to myosin heads and stimulate activation of the GTPase without 
phosphorylation of MLC-20 (Gao 2003).  
 Inhibition of MLCP prevents it from dephosphorylating MLC-20 and causes an increase 
in contraction.  Activation of the phosphatase will, of course, lead to relaxation.  Many G-
proteins activate phospholipase A2 (PLA2), which cleaves arachidonic acid (AA)—a fatty acid 
(FA)—from phospholipids (PLs).  Arachidonic acid causes dissociation of the MLCP 
holoenzyme into its constituent subunits: the regulatory subunit (MYPT-1), the catalytic subunit 
(PP-1), and a 20 kDa subunit of unknown function (Gong 1992; Alessi 1992; Shirazi 1994; 
Shimizu 1994; Haystead 1995; Gailley 1996; Harthorne 1998 [review]).  The regulatory subunit, 
which targets MLCP to MLC-20 remains in the cytosol, while the catalytic subunit translocates 
to the cell membrane, where it experiences a reduced catalytic activity.  
 
 
 
 
 
 
 
 
 
 
 
Relaxation Pathways in SM 
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*Phosphorylation of MLCK at alternative sites causes: 
-Decreased affinity for Ca-CaM 
 
Figure 9:  Diagram illustrating the signal transduction pathways of relaxation in SM cells. 
 
MLCP is also inhibited by the phosphopeptide CPI-17, when it is activated by 
phosphorylation (Harshorne 1998).  It has been hypothesized that many kinases—ROK, PKC, 
and ZIP-like kinase—phosphorylate and activate the peptide as a means of inhibiting MLCP 
(Kanecko 2001; Eto 1995; Kitazawa 1999; Gailly 1997; (Macdonald 2001a; Ichikawa 1996a; 
Pfitzer 2001; Trinkle-Mulcahy 1995). 
 Phosphorylation of the catalytic subunit (MYPT-1) of MLCP inhibits its function.  This 
task is performed by many kinases, including ROK (Feng 1999; Kimura 1996), ZIP-like kinase 
(Ichikawa 1996; MacDonald 2001b), unidentified kinases sensitive to staurosporine-induced 
contraction (Kureishi 1999, Weber1999), and other unidentified kinases (Feng 2000; Somlyo 
1999).  
 In terms of activation, it has been proposed that either cGMP directly activates MLCP 
(Surks 1999) or does so through phosphorylation of telokin, which activates MLCP (Wu 1998). 
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 IP3/DAG Signaling  
 Inositol-triphosphate (IP3), a negligible signal in skeletal muscle (Pape 1988), has been 
confirmed as a secondary messenger in the contraction of smooth muscle by many sources 
(Kobayashi 1989; Hashimoto 1986; Miller-Hance 1988; Somlyo 1992, 1988).   
 
IP3/DAG Signaling in SM 
 
 
 
Figure 10:  Diagram illustrating the signaling pathways of IP3/DAG in SM cells. 
Most excitatory agonists are coupled by G-proteins that activate phospholipase-beta 
isoform (PLC-β), which cleaves phosphoinositol (PPI)—a phospholipid—into IP3 and 
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diacyglycerol (DAG) (Figure 6).  Generally, the G-proteins that activate the PLC-β pathway also 
inhibit nucleotide cyclases, which will be discussed later (Somlyo 1994).  Activators of PLC-β 
include AA (Husain 1998, 1999), some tyrosine kinases (Zhou 1993), and phorbol esters (Jensen 
1996; Walker 1998).   
 
 
 
 
Figure 11:  Structures of inositol-triphosphate (IP3) and diacylglycerol (DAG). 
  
 
 
IP3 activates IP3-receptor Ca2+-channels in the SR (Somlyo 1994).  DAG activates PKC, 
which induces contraction by phosphorylating CPI-17, the MLCP inhibitor (Eto 1995; Kitazawa 
1999; Gailly 1997).  It can also phosphorylate the G-protein Raf, which acitvates MAPKK 
(Neary 1997).  Arachidonic acid can also activate PKC (Gong 1992, 1995). 
IP3 can be phosphoryated by IP3 kinase to produce the inactive IP4.  The IP3 receptor is 
phosphorylated by cAMP-dependent protein kinase (PKA), cGMP-dependent protein kinase 
(PKG), or CaM KII (Patel 1999).  The pathway is also inhibited by heparin (Kobayashi 1989).     
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 On a side note, time delays between agonist-induced receptor activation and tension 
development ranges from 200-500 ms.  This delay is probably due to diffusion and reaction of 
signaling molecules (IP3 production, diffusion of Ca-CaM).  It is not limited by the act of MLC-
20 phosphorylation (Somlyo 1990). 
 
 
cAMP/cGMP Signaling  
  
The main secondary messengers for inducing relaxation are elevated levels of cAMP 
(cyclic adenosine monophosphate) and/or cGMP (cyclic guanosine monophosphate) (Karaki 
1988; Kerrick 1981; Morgan 1984; Pfitzer 1986; Seguchi 1996; van Riper 1995).  Receptors are 
activated and stimulate adenylyl/guanylyl cyclases, which catalyze the formation of 
cAMP/cGMP from ATP (adenosine triphosphate) or GTP (guanosine triphosphate) precursors 
(Pftizer 1984) (Figures 7and 8, below).   Adenylyl cyclase is activated by many Gβγ-protein 
receptors, and inhibited by many Gα-protein receptors.  Some stimulants of relaxation through 
the cAMP pathway include forskolin (Abdel-Latif 1996), Nitric oxide (NO), atrial natriuretic 
peptide, and (ERF) (Lincoln 1996).   
 
Figure 12:  Conversion of Adenosine-triphosphate (ATP) into cyclic Adenosine-monophosphate (cAMP), 
catalyzed by adenylyl cyclase. 
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 cGMP 
Figure 13:  Structure of cyclic guanosine-monophosphate (cGMP). 
 
 
 
Cyclic Nucleotide (cAMP/cGMP) Signaling in SM 
 
 
 
The effect of 4 × [cAMP] = [cGMP]. 
 
Figure 14:  Diagram illustrating the signal transduction pathways of cAMP and cGMP in SM cells. 
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cAMP activates cAMP-dependent protein kinase (PKA) and cGMP activate cGMP-
dependent protein kinase (PKG).  There is evidence that cAMP may also activate PKG (Kotikoff 
1996).  Studies have also shown that four times the concentration of cAMP is required to cause 
50% relaxation of vascular smooth muscle than cGMP (Dhanukoti 2000).    
 Increased levels of these cyclic nucleotides may cause reduction in cytosolic [Ca2+], via 
1) Inhibition of PLC-β, and thus IP3 production, 2) Inhibition of Ca2+ channels, 3) Activation of 
Ca2+ pumps in the PM and SR to remove Ca2+ from the cytosol (Abdel-Latif 2001).  The 
secondary messengers have also been shown to increase the frequency of Ca2+-sparks (Porter 
1998).   
PKA/PKG can phosphorylate and inhibit PLC-β (Abdel-Latif 1996; Liu 1996) if it is 
anchored to the membrane by putative A kinase anchoring protein (AKAP86) (Dodge 1999).  
PKA/PKG can phosphorylate the G-protein Raf which stimulates mitogen-activated protein 
kinase kinase (MAPKK), but it is not clear whether this causes an inhibitory effect (Bornfeldt 
1999; Cspedel 1999; Abdel-Latif 2001).  Curiously, it has been found that cGMP may actually 
activate MAPKK, but the implications of this are not known (Komalavilas 1999; Kim 2000; Ho 
1999).   
PKA/PKG is capable of phosphorylating the GTPase protein RhoA to inhibit the Rho 
Kinase pathway, to be discussed later (Sauzeau 2000).  PKA/PKG may also phosphorylate heat 
shock protein 20 (HSP-20), which directly inhibits the MgATPase, causing relaxation (Rembold 
2000).   
 The pathway may also inhibit contraction by activating MLCP through phosphorylation 
of telokin, which activates the phosphatase (Wu 1998), and cGMP may activate MLCP directly 
(Lee 1997).   
  
RhoA/Rho Kinase Signaling  
 
 Another important regulatory and recently studied pathway that is independent of [Ca2+] 
is the RhoA/Rho kinase (ROK) pathway. RhoA is a small GTPase that is inactive when bound to 
GDP, and active when bound to GTP.  Guanidine nucleotide dissociation inhibitors (GDIs) bind 
to RhoA-GDP in the cytosol (Gosser 1997; Longenecker 1999).  The exchange of GDP for GTP 
is catalyzed by guanidine exchange factors (GEFs), which causes the GDI to dissociate (Kozasa 
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1998; Hart 1998).  This facilitates the translocation of RhoA-GTP to the PM (Gong 1997; 
Fuijhara 1997; Read 2000; Cherfils 1999).   
 
Rho Signaling in SM 
 
 
  
Contraction = Tonic Phase Contraction 
 
Bacterial Toxins (Reviewed-Sehr, 1998) 
Clostridium Botulinum:  ADP-ribosylation of RhoA at Asn-41 
Clostridium Difficile:  Monoglucosylates Thr-37 of RhoA 
 
*Calcium-Independent Regulation of Contraction (Calcium Desensitization) 
 
Figure 15:  Diagram illustrating the signaling pathways associated with RhoA/ROK in SM cells. 
  
Many trimeric G-proteins activate the RhoA pathway by stimulation of GEFs (Katoh 1998; 
Croxton 1998; Klages 1999; Hirshman 1999).  It has also been found that tyrosine kinase 
inhibitors inhibit RhoA translocation to the PM, indicating that the pathway can be activated by 
tyrosine kinase receptors, as well (Sakurada 2001).  U-46619 has also been shown to activate the 
pathway (Bradley 1987; Himpens 1988; Himpens 1990). 
 22
The active RhoA-GTP activates Rho kinase (ROK).  However, activation requires that 
both units be translocated to the plasma membrane (Leung 1995; Gong 1997; Fujihara 1997; 
Taggart 1999).  ROK can also be activated by AA (Fu 1998; Feng 1999).  ROK induces 
contraction by phosphorylating and inhibiting MLCP (Kimura 1996; Feng 1999).  ROK can also 
phosphorylate calponin (Katoch 1997) and CPI-17, which inhibits MLCP, as well (Koyama 
2000; Kanecko 2000). 
Ca2+ sensitization facilitated by RhoA/ROK signaling only affects tonic SM contraction 
(Somlyo 2000).  Inhibition of the pathway results in relaxation.  Several points of inhibition have 
been observed.  Some bacterial toxins can inhibit the translocation of RhoA-GTP to the PM.  
The toxin from Clostridium botulinum causes ADP-ribosylation at asparagine 41 (Asn-41)of the 
protein and that from Clostridium difficile causes monoglucosylation at threonine 37 (Thr-37) of 
RhoA (Fujihara 1997; Gong 1997).  Y-27632 is a specific inhibitor of ROK (Uehata 1997; 
Somlyo 1997; Yoshi 1999; Fu 1998; Nakahara 2000). Rnd1 has properties that are antagonistic 
to RhoA, and inhibits the pathway (Loirand 1999).  Also, hydrolysis of GTP complexed with 
RhoA to GDP, or re-complexation with GDI inhibits the pathway (Longenecker 1999).  
It is interesting to note that the very specific Y-27632 ROK inhibitor has been shown to 
reduce blood pressure in hypertensive rats, but has no effect on normal rats (Uehata 1997), 
implicating that an overactive Rho pathway may cause some cases of high blood pressure.  Use 
of the inhibitor as a drug is being investigated (Somlyo 1997).  
It has been proposed that ZIP-like kinase—known to phosphorylate MLCP, and 
phosphorylate and activate CPI-17 (Macdonald 2001a; Ichikawa 1996a; Pfitzer 2001; Trinkle-
Mulcahy 1995)—is a downstream link between PKC, ROK, and inhibition of MLCP.  Two 
problems for direct phosphorylation of MLCP by ROK occur.  First, the major phosphorylated 
site on MLCP is not inhibitory (Kitazawa 2002).  Also, both RhoA-GTP and ROK are located at 
the PM, and MLCP is cytosolic (Pfitzer 2001).  Thus, ZIP-like kinase has been found to co-
purify with MLCP (Ichikawa 1996a), and is inhibited by ROK inhibitors and PKC inhibitors.  
So, it has been proposed as the missing link between converging pathways (MacDonald 2001a).   
 
MAPK Signaling 
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 Mitogen-activated protein kinase (MAPK) signaling has been more recently implicated in 
SM contraction.  p42/p44 MAPK can directly phosphorylate MLC-20 (Takahashi 1998; Dessy 
1998; Ohmichi 1997; Velarde 1999; Yousufzai 2000; Dechert 2001).  It was found that potent 
inhibitors of the kinase inhibited PF2-induced contraction, but not IP3 production (Yousufzai 
1998), leading to the postulation that direct phosphorylation of MLC-20 is most important 
(Abdel-Latif 2001). 
 
MAPK Signaling in SM 
 
 
Figure 16:  Diagram illustrating the signal transduction pathways associated with MAPK in SM cells. 
 
 
MAPK signaling is induced by some G-protein receptors (Sah 2000).  The complete 
mechanism leading to the MAPK cascade is still unclear (Abdel-Latif 2001).  However, they 
may be facilitated by activation of the G-protein Ras, which activates Raf.  Raf phosphorylates 
MAPKK, which phosphorylates MAPK (Neary 1997).   
 p42/p44 MAPK can also phosphorylate MLCK (Klemke 1997) to increase its activity.  It 
has also been found to phosphorylate caldesmon (CaD) to cause its dissociation from F-actin.  
The effect of this dissociation is not, however, believed to have a large influence on contraction, 
as of now (Pearce 2003). 
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Other Regulatory Proteins 
 
 Calmodulin Kinase II (Cam KII) is activated when complexed with Ca2+ at a higher 
concentration than needed to activate MLCK (Tansey 1994).  It can phosphorylate and inhibit 
MLCK to serve as a source of negative feedback for levels of Ca2+ that are too high, thus 
avoiding overconstriction (Word 1994).  Autophosphorylation of Cam KII causes the effect to 
continue after [Ca2+] levels have fallen (Somlyo 1994).  Cam KII also activates MAPKK 
(Katoch 1999).   
 Phorbol esters stimulate contraction when added to SM tissue, and were the agonist used 
for studies conducted in this research, to be discussed later.  They induce a modest increase in 
the level of MLC-20 phosphorylation (Itoh 1993), through activation of PKC, possibly 
phosphorylation of CaD (Adam 1992), or through activation of PLA2, and subsequent release of 
AA.  Slow phosphorylation of MLC-20, and slow development of tension at lower levels of 
MLC-20 phosphorylation are associated with contraction induced by phorbol esters (Itoh 1993), 
which has been proposed as an extreme case of latch (Somlyo 1994).  
 
Caveolae 
 
 An interesting recent discovery is that of caveolae—specialized gathering platforms of 
various shape.  These platforms are composed of phopholipids and have been found in SM cells.  
It has been suggested that these platforms serve as meeting centers for interacting regulatory 
proteins involved in SM contraction, and are required for proper function of contraction, at least 
(Taggart 2001).  Severe contraction disorders were observed in mice with a deficiency in 
caveolae (Drab 2001).  Such caveolae may be important in other cell types and functions as well.  
More research needs to be done. 
Study of SM 
 
 As noted, SM demonstrates slightly different mechanistic properties.  These properties 
are a function of its ultrastructural design and the biochemistry of its proteins.  This project was 
begun in conjunction with colleagues Wright et al. from the Department of Physiology, Joan C. 
 25
Edwards School of Medicine (MUSOM), for the purpose of providing a comprehensive, global 
study of SM tissue.  Wright et al. have investigated the mechanistic properties and dynamics of 
SM activity (including cytoskeletal rearrangement/remodeling of actin/myosin filaments, 
translocation of PKC within the cell, etc.) using confocal microscopy and methods similar to 
those mentioned previously (see smooth muscle mechanics), (Recent publications: Dykes 2003; 
Fulkz 2003; Wright 2002; Li 2002, 2001a, 2001b; Geng 2001a/2001b; Fulkz 2000; Fung 2000; 
Battistella-Patterson 2000; Wang 2000).   
This composition focuses on the biochemistry of SM tissue at the level of the proteome.  
Operational behavior and regulation of the motor cross-bridges that facilitate motility and 
contractile properties occurs at the molecular level. 
The complexity of the multiple pathways explains why such slow progress has been 
made on the understanding of signaling cascades in SM contraction. Different inhibitors and 
agonists of contraction converge at different points in the pathways.  Much research has been 
done and is still being done on the effects of different agonists and receptor activation on 
contraction/relaxation (for example:  Lincoln 1996; Luo 1997; Yang 1998; Yang 1999; de 
Alencar 2003.  Reviews: Abdel-Latif 2001; Fernandes 2003; Koshimizu 2003).   
Many traditional techniques have been utilized in the study of SM, such as cell culture 
and transgenic animal models coupled with gene transfections, and site-directed mutagenesis (for 
example: Yanboliev 2001; Cherie 2002; Hedges 2000, 1998; Dechert 2001).  The physical 
dynamics of depolarization, Ca2+ levels in the cell, and protein translocation have also been 
probed, using such techniques as electrical field stimulation (EFS), patch clamps, and 
fluorescence confocal microscopy (for example: ZhuGe 2000; Huang 2003; Wang 2003; Dykes 
2003; Fultz 2003; Li 2002).  However, a major problem with this microscopy is that fluorescent 
indicator dyes must bind the cytosolic calcium in the cell.  This binding removes Ca2+ from the 
cytosol and may greatly perturb the homeostasis of the system, affecting the accuracy of 
measured properties.  Electron probe X-ray microanalysis allows the intracellular localization 
and transport of cellular components to be monitored (Review: Somlyo 2000).  Extensive 
research is still conducted on the level of myosin phosphorylation, as well (for example: 
Facemire 2000; Sobieszek 2001). 
 
Proteomics 
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 Although progress has been made using such techniques, it has been slow progress.  
Investigating each step individually takes more time.  That is why it becomes necessary to 
develop a means of investigation that utilizes a broader perspective of the biological system.   
This investigation focuses on the analysis of signal transduction at the proteome level 
through differential phosphorylation—the primary means of communication and activity 
modification of proteins.  Protein phosphorylation serves as the on/off signal for many, if not 
most, of a cell’s activities.  The proteomic approach coupled with mass spectrometry (MS) 
analysis allows for high-throughput investigation of multiple proteins within a pathway, offering 
a glimpse of the entire picture of cellular activities under a given set of conditions.  It must be 
emphasized that cellular communication does not occur linearly along a single pathway, but 
branches into multiple associations of messenger molecules and proteins.  The pathways are 
interconnected.   
This approach opposes the standard reductionist perspective of analysis in which isolated 
steps or individual proteins/enzymes are investigated.  Such considerations explain why it has 
become necessary to incorporate the big picture into analysis.  The proteome may be described 
as the sum of proteins expressed by a specific cell or tissue type under given physiological 
conditions.  Proteins are the machinery which perform the vital functions that make life possible.  
Dysfunctional proteins are frequently the pathogen behind many human disorders.  
The human genome project (HGP) has provided a comprehensive starting point for 
investigation.  However, the genome provides only the blueprints for the cell’s activities, 
furnishing a two-dimensional model that is often not straightforward.  Not everything encoded in 
the blueprint goes into the finished product, and modifications are made along the way.  After 
mRNA processing and post-translational modifications, the protein product is no longer 
equivalent to its gene complement.  Proteins are often manufactured as nonfunctional pre-
proteins, often with signaling peptides that instruct where it should be shipped to in or outside 
the cell.  A peptide is clipped off the before the protein can fold correctly into the functional 
product.  
 With the capabilities of modern proteomic techniques the entire proteome of a cell can be 
viewed and investigated at once.  Structural information and physical characteristics of proteins 
can be obtained using proteomic/MS analysis (see Appendix II).  In general, proteomics 
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involves: 1) separation/isolation of proteins, 2) purification of analyte, and 3) analysis (see 
Appendix III).   
 The proteomic techniques used in this study were based on methodology developed by 
the research of Neal (2001) at Marshall University, with alteration of protocols, as necessary.   
  
Phosphoproteomics 
 
Phosphoproteins were specifically targeted for the purpose of this investigation.  As has 
been demonstrated and discussed in the preceding pathways, differential 
phosphorylation/dephosphorylation is a very important means of signal transduction and 
regulation in SM tissue.  However, because of the standard analytical methods used thus far, few 
of the actual phosphorylation sites within these proteins are known (Appendix VI).   
Phosphoryation of a protein or peptide occurs at serine, threonine, and/or tyrosine 
residues (Appendix V), and is mediated through a kinase.  Dephosphorylation is catalyzed by a 
phosphatase, (Figure 17). 
 
 
Figure 17:  Illustration of the phosphorylation/dephosphorylation of serine. 
  
Specific methodology exists for the analysis of phosphopeptides/proteins, including 1 ) 
means of detection and identification of phosphomoieties, 2) allocation of phosphorylation sites, 
3) selective isolation of phosphopeptides, and 4) derivitization of phosphopeptides/proteins. 
Detection of phosphoproteins can be done on a 1D or 2D SDS-PAGE gel, either by specific 
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phosphoprotein stains, such as the ProQ Diamond Phosphoprotein Stain by Molecular Probes 
(Martin 2003), or via detection of autoradiography from cell lysates treated with radioactive 
isotopes of phosphorous (P33, P32). The latter method was based on a SM phosphorylation study 
done by Takuwa et al., in which several differentially phosphorylated proteins were noted, but 
not identified (Takuwa 1988).  This was the initial driving force for the approach.  However, the 
technique poses much more of a hassle due to the hazards and safety precautions associated with 
working with radioactive materials.  It is also more expensive due to the high cost of radioactive 
P33.  Both methods have been explored in this research.   
 After phosphoproteins are subjected to proteolytic digest by an endoprotease, 
phosphopeptides can be selectively isolated through the use of Fe3+-IMAC (Immobilized metal 
affinity chromatography) at relatively low expense. Phosphopeptides are negatively-charged 
species that demonstrate a high affinity for Fe3+ (Posewitz 1999).  Other negatively-charged 
peptides—such as highly acidic peptides—are also bound by the IMAC.  However, this problem 
can be circumvented if carboxylic acid groups are esterified prior to IMAC separation (Ficarro 
2002).   
Low stochiometric abundance of phosphopeptides makes them more difficult to detect.  
Pre-isolation of such peptides increases their relative abundance in mass spectra, as interference 
of the more abundant non-phosphorylated peptides is removed. This methodology is known as 
enrichment, and has been used in many applications (Cao 2000; Stensballe 2001; Ficarro 2002; 
Raska 2002; Rocher 2003). 
A condition for the analysis of phosphopeptides in positive ion mode is a low pH solution 
(see Appendix II).  An acidified solution will facilitate protonation of phosphate groups, and 
allow molecular ions to obtain a net positive charge.  Phosphoproteins normally carry a negative 
charge, which makes them hydrophillic, as well.  This makes reverse-phase HPLC less efficient, 
which is set up to purify hydrophobic peptides.  Therefore, it is best to purify phosphopeptides 
on a special column, such as the POROS OligoR3 (Wilm 1996; Neubauer 1999). 
 Many other methods for characterization of phosphoproteins/peptides exist, but were not 
investigated in this research.  Direct dephosphorylation of peptides in triple quad mass 
spectrometers is an excellent example of the capabilities of more advanced instrumentation.  
Only a MALDI-TOF instrument was used in this work.   
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 Phosphopeptides can also be reacted with various agents to create an analyzable 
derivative.  Oxidation of the carbon-carbon (C-C) bond coupled with loss of the phosphate group 
next to it is termed β-elimination.  This reaction is usually facilitated by the alkaline metal 
barium hydroxide (BaOH2), because of its greater efficiency at lower concentration than would 
be required of sodium hydroxide (NaOH) (Figure 18).  Serine, threonine, and carbamidocysteine 
residues are also safe against hydrolysis by BaOH2, though free cysteines (CH3SH) and cystines 
(CH3S-SCH3) are not (Bydford 1991).   
 
 
 
 
 
 Figure 18:  β-elimination of phosphate groups from a peptide using a barium hydroxide (BaOH2) catalyst, 
where Rc = C-terminal portion of peptide, and Rn = N-terminal portion of peptide. 
 
 
 
 
 
Groups can then be added across the double bond via Michael addition to create useful 
derivatives, such as 2-aminoethanethiol or ethanedithiol (Figure 19).  Derivitized peptides can be 
identified with MS and post source decay (PSD) (see Appendix II).  The group can also be 
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oxidized off, leaving a neutral peptide to help confirm identification (Cole 1967; Mega 1996, 
1990; Adamczyk 2001; Goshe 2001Rusnak 2002; Steen 2002, 2003) (Figure 20).   
 
 
 
 
Figure 19: Michael addition of the nucleophillic 2-aminoethylthiol across the double bond of the peptide, creating a 
lysine-like residue, where Rc = C-terminus of peptide, and Rn = N-terminus of peptide.  
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Figure 20:  Oxidation of the lysine-like residue produces a sulfur-oxygen double bond which then dissociates from 
the peptide, finally leaving an alanine residue.   
 
Another exciting and innovative capability of this method lies in the capacity of the 2-
aminoethylcysteine derivatives (Figure 19) to be proteolytically cleaved by endoproteases 
specific for lysine—trypsin.  Subsequent analysis of the fragments with MS will allow 
determination of phosphorylation sites within peptides with more than one serine/threonine 
residue, because only a phosphorylated Ser/Thr residue will be derivitized and cleaved.  
However, the technique is not useful for analyzing tyrosine phosphorylations.   
 In this research, the tonic phase of contraction, facilitated by prolonged exposure to an 
agonist, was investigated using aortic SM tissue from Sprague Dawley rats.  It should be noted 
that due to prolonged exposure, functional remodeling of actin filaments and delayed relaxation 
post-contraction can occur, as was investigated by our colleagues at MUSOM.   
Differential phosphorylation in resting and phorbol-contracted (Figure 21) tissue was 
probed using a phosphoproteomic approach coupled with MALDI-TOF MS.  The goal was to 
look at the whole proteome and the signal transduction pathways there involved.    
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Figure 21:  Structure of phorbol—the agonist used to contract the aortic SM tissue in this research. 
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MATERIALS  
 
 
Materials 
 
COMPANY MATERIALS 
American National Corp. (Chicago, IL) -Parafilm 
Becton-Dickinson (Franklin Lakes, NJ) -Polystyrene conical tubes (15/50 mL) 
BioRad (Hercules, CA) -Eppendorf pipets 
-Ready gels 
Fisher (Pittsburgh, PA) -Redi-tips (1-10µL, 1-200µL, 1000µL) 
- Alkacid pH test paper 
- Microcentrifuge tubes (0.5 mL, 1.5 mL) 
Genomic Solutions (Ann Arbor, MI) -microtiter plates 
Harvard Biosciences (Holliston, MA) -DisposoBioDialyzers 
Kimberly-Clark Corporation (Irving, TX) -Kimwipes Ex-1 
Millipore (Billerica, MA) -ZipTips 
Scientific Product (Cambridge, MA) -Eppendorf pipets 
 
 
 
Reagents 
 
COMPANY REAGENTS 
Acros Organics (Pittsburgh, PA) -Acetone 
-Acetonitrile 
-Acetic acid (HPLC grade) 
-Glacial Acetic acid 
-EDTA 
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-Formic acid 
-H2O2 
-Isopropanol 
-Iodoacetamide 
-Methanol (HPLC grade) 
-Sodium carbonate 
BioRad Lab. (Hercules, CA) -Silver stain plus kit 
-SYPRO ruby  protein gel stain 
-Dithiothreitol 
-Prestained Precision protein stds.  
-Tris/Glycine/SDS buffer 
-Laemmili Sample Buffer 
Bruker-Daltonics (Billerica, MA) -HCCA 
-Sinapinic acid 
-peptide calibration stds.  
Fisher-Scientific (Pittsburgh, PA) -Ammonium acetate 
-Ammonium bicarbonate 
-Ammonium hydroxide 
-Dibasic sodium phosphate (Na2PO4) 
-Monobasic potassium phosphate (KH2PO4) 
-Dibasic potassium phosphate (K2H PO4) 
- ethylenediaminetetraacetic acid (EDTA) 
-Glycerol 
-Magnesium chloride (MgCl2) 
-Calcium chloride (CaCl2) 
-Sodium bicarbonate (NaHCO3) 
-Sodium chloride (NaCl) 
-SDS 
-Sodium thiosulfate 
-Triethanolamine 
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- Tris 
-Potassium chloride (KCl) 
-Potassium ferricyanide 
-Urea 
-pH buffer std solutions (pH 4.00, 7.00, 10.00) 
Genomic Solutions (Ann Arbor, MI) -Pre-cast duracryl slab gels 
-Pre-cast carrier ampholyte pH 3-10 tube gels 
-Pre-cast immobilized pH gradient pH 3-10                   
      tube gels 
-IEF Anode Concentrate (85% phosphoric acid) 
-IEF Cathode Concentrate (10.0 N sodium hydroxide) 
- IPG Urea/Thiourea Solubilization/Rehydration     
      Buffer 
-Sample Buffer I 
-Sample Buffer II 
-Sample Buffer III 
-Tris-acetate buffer—25x concentration 
-Tris-acetate equilibration buffer 
-Tris/Tricine/SDS running buffers 
ICN Pharmaceuticals (Costa Mesa, CA) -Actin (rabbit muscle) 
-Ketamine 
-Xylazine-20 
Kodak - XOMAT-AR film (8” × 10”) for autoradiography 
Molecular Probes (Eugene, OR) -ProQ Emerald 300 Glycoprotein stain Kit 
-ProQ Diamond Phosphoprotein stain 
-SYPRO Ruby Protein Stain  
Pierce (Rockford, IL) -GelCode Blue Protein Stain reagent 
Sigma-Aldrich (St. Louis, MO) -Brilliant Blue G (Coomassie Protein Stain) 
-Trifluoroacetic acid 
-Myoglobin  
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-β-Mercaptoethanol 
-Proteoprep Universal Extraction Kit 
-Sodium Phosphate 
-Trypsin—Proteomics grade 
 
 
 
Instrumentation 
 
COMPANY INSTRUMENT 
Applied Biosystems (Foster City, CA) -130A Separation System HPLC 
Barnstead (Boston, MA) -Nanopure Infinity—Ultrapure water system 
BioRad Lab (St. Louis, MO) -Ready Gel Cell  (1D SDS-PAGE) 
-GelDoc w/ Quantity One software 
Bruker-Daltonics (Billerica, MA) -Biflex III  (MALDI-TOF MS) 
Denver Instruments (Denver, CO) -M-220D Electronic Balance 
Fisher-Scientific (Pittsburgh, PA) -Dry Bath Incubator 
-FS30 Sonicator 
-Micro-7 Microcentrifuge 
-Vortex Genie 
Forma-Scientific (Marietta, OH) -Lab/Pharmacy Freezer  
Genomic Solutions (Ann Arbor, MI) -ProGest Investigator (version 2.01.15) 
-ProPic Ivestigator Imager/Robot picking w/  
       Investigator HT Analyzer software 
-Investigator 2D Electrophoresis system w/ 
       Investigator 5000 Programmable Power 
       Supply 
Lab-Line Instruments (Boston, MA) -Shaking bath 
Savant Instruments (Holbrook, NY) -SpeedVac SC110 vacuum microcentrifuge w/ 
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        refridgerated vaportrap RVT 4104 
-µSpeed Fuge SFR13K refridgerated 
microcentrifuge 
Thermo-Finnigan (San Jose, CA) -LCQ 
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BUFFERS AND SOLUTIONS  
Krebbs Buffer (Incubation medium) 0.184 g  CaCl2 x H2O  
0.29 g MgCl2 
6.90 g NaCl 
0.35 g KCl 
0.16 g KH2PO4 
2.1 g NaHCO3 
0.9 g glucose  
    -1 Liter H2O                            (37°C) 
Lysis Buffer 500 µL  Tris (0.1 M) 
500 µL Glycerol (1mg/mL) 
10 µL EDTA (0.5M) 
5 µL Lupeptin (1 mg/mL in PBS) 
5 µL Pepstatin (17.4 mg/mL in EtOH) 
5 µL Aprotinin (1 mg/mL in EtOH) 
25 µL PMSF 
     -5 mL PBS               
RIPA Buffer 50 mM Tris-HCl, pH 7.4 
1% NP-40  
0.25% Sodium Deoxycholate 
150 mM NaCl 
1 mM EDTA 
1 mM PMSF 
1 µg/mL aprotinin 
1 µg/mL leupeptin 
1 µg/mL pepstatin 
1 mM Na3VO4 
1 mM NaF 
Phosphate Buffered Saline (PBS) 8.0 g NaCl 
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0.2 g KCl 
0.115 g Na2PO4 
0.2 g K2HPO4 
0.1 g CaCl2 (Anhydrous) 
0.1 g MgCl2 
     -1 L H2O 
Ketamine 100 mg/mL 
Xylazine-20 20 mg/mL 
Radioactive Phosphorous Solution 10 mCi P33/ 0.5 µL H3PO4 
Phorbol Solution 10 nm Phorbol in DMSO   
10 µm Phorbol in DMSO (Excess) 
Proteoprep Universal Extraction Kit (Sigma- 
     Aldrich) 
-Soluble Cytoplasmic Extraction Reagent 
-Cellular and Organelle Membrane 
Solubilizing  
      Reagent 
-Soluble Protein Resuspension Reagent 
Dialysis Buffer I  1.84 g Tris 
5.8 g NaCl 
    -1 L H2O 
Dialysis Buffer II Nanopure H2O 
Laemmili Sample Buffer 62.5 mM Tris-HCl 
2% SDS 
25% Glycerol 
0.01% Bromophenol blue 
Tris/Glycine/SDS Buffer (1D SDS-PAGE) 25 mM Tris-HCl  
192 mM Glycine  
0.1% SDS 
Sample Overlay Buffer  0.5 M Urea 
0.2% Triton X-100 
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0.1% Ampholytes       
50 mM DTT             (1/20 Sample Buffer Mix) 
Sample Buffer I  0.3% SDS 
200mM DTT 
28 mM Tris HCl 
22 mM Tris Base                    (Store -70° C) 
Sample Buffer II 24 mM Tris Base 
476 mM Tris HCl 
50 mM MgCl2 
1 mg/mL DNAse I                  (Store -70° C) 
Sample Buffer III 9.9 mM Urea 
4% Triton X-100 
2.2% Ampholytes 
100 mM DTT                         (Store -70° C)        
Sample Buffer Mix    80 mL Sample Buffer III  
+ 20 mL Sample Buffer I 
7.92 M Urea                
0.06% SDS  
1.76% Ampholytes 
120 mM DTT 
3.2% Triton X-100 
22.4 mM Tris HCl 
17.6 mM Tris base                 (Store -70° C) 
Modified Sample Buffer Mix Sample Buffer Mix 
1.5% SDS 
150 mM DTT 
IEF Cathode Buffer (1st Dimension of 2D) 100 mM NaOH 
IEF Anode Buffer 10 mM H3PO4 
IPG Urea/Thiourea Solubilization/Rehydration  7 M Urea 
 41
    Buffer 2 M Thiourea 
2% CHAPS 
65 mM DTT 
1% Zwittergent 
0.01% Bromphenol Blue 
0.80% Ampholytes (pH 3-10) 
IPG Equilibration Buffer I 6 M Urea 
130 mM DTT 
30% Glycerol 
45 mM Tris Base 
1.6% SDS 
0.002% Bromphenol Blue 
--pH 7 
IPG Equilibration Buffer II 6 M Urea 
135 mM Iodoacetamide 
30% Glycerol 
45 mM Tris Base 
1.6% SDS 
0.002% Bromphenol Blue 
--pH 7 
Tris/Acetate Equilibration Buffer 0.112 M Tris 
5 % SDS 
0.1 % Bromophenol blue 
50 mM DTT                          (Refridgerated) 
2D SDS-PAGE Cathode (2nd Dimension of 
2D) 
0.2 M Tris  
0.3 M Tricine 
0.4 % SDS                            (Refridgerated)      
2D SDS-PAGE Anode 25 mM Tris/Acetate              (Refridgerated) 
Coomassie Brilliant Blue Stain  0.25 g Brilliant Blue R250 
40 mL  MeOH 
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50 mL H2O 
10 mL Glacial AcOH                      (Filtered)  
Coomassie Fixing/Destain  40% MeOH 
50% H2O 
10% Glacial AcOH 
Silver Stain Fixing Solution  50% MeOH 
10% AcOH 
10% BioRad Fixative Enhancer Concentrate     
        (Silver Stain Plus Kit) 
30% H2O 
Silver Stain  (BioRad Silver Stain Plus Kit) 15.0 mL Silver Complex Solution  
15.0 mL Reduction Moderator Solution 
15.0 mL Image Development Reagent 
105 mL H2O 
150 mL Development Accelerator Solution 
Silver Destain 30 mM K2Fe(CH)6 in 100 mM Na2SO3 
Silver Stain Stop Solution 5% AcOH 
SYPRO Ruby Fixing/Destain Solution 10% MeOH 
7% AcOH 
SYPRO Ruby Protein Gel Stain Use as is.   
GelCode Blue Protein Stain Use as is. 
GelCode Blue Destain H2O 
ProQ Diamond Phosphoprotein Gel Stain Use as is.                      (Keep from light) 
Phosphoprotein Fixing Solution 10% TCA  
50% MeOH 
Phosphoprotein Destain Solution 50 mM Sodium Acetate 
4% AcCN 
Tryptic Digest Solutions—Manual Washing/swelling—100 mM NH4HCO3 
Drying/shrinking—AcCN  
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Reduction—10 mM DTT in 100 mM  
       NH4HCO3 
Modification—55 mM Iodoacetamide in 100  
       mM NH4HCO3 (Light protected) 
Digestion—2 µg/mL trypsin in 40 mM  
        NH4HCO3 
Tryptic Digest Solutions—ProGest Washing/swelling—40mM mM NH4HCO3 
Drying/shrinking—AcCN  
Reduction—10 mM DTT in 40 mM  
       NH4HCO3 
Modification—100 mM Iodoacetamide in 40  
       mM NH4HCO3 (Light protected) 
Digestion—20 µg/mL trypsin in 40 mM  
        NH4HCO3 
HPLC Base Solvent 70% AcCN 
0.85% Glacial AcOH 
~30% H2O 
HPLC Water Solvent 0.1% AcOH 
~100% H2O 
ZipTip (C-18)  Solutions Wetting—50% AcCN 
Equilibration—0.1% TFA 
Wash—0.1% TFA 
Elution—70% AcCN in 0.1% TFA 
MALDI-TOF Matrix Solutions (Two Layer 
Spottin) 
1st Layer solution—5 mg/mL HCCA in 50% 
acetone 
2nd Layer solution—Saturated HCCA in 50% 
AcCN 
 
*Solutions were prepared with >17 MΩ nanopure water. 
METHODS 
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*Procedures were performed at room temperature, unless specified otherwise in the 
protocol.   
 
I. Sample Preparation 
 
Dissection/Tissue Extraction 
 Male Sprague dawley rats of approximately the same size and weight were anesthetized 
with ~0.75 mL 2:1 Ketamine:Xylazine (100 mg/mL:20 mg/mL).  Rats were obtained from 
MUSOM, care of Dr. Gary Wright and/or Dr. William McCumbee.  Filled the tip of a syringe 
with ~20 mL heparin sodium, and drew blood from the heart, ~12 mL.  Living aortic tissue was 
then surgically removed, and thoroughly cleaned of any adherent material.  Tissues were 
temporarily stored/incubated in Krebbs buffer, 37°C. 
 
Radioactive Phosphorous Labeling 
 Excised aortas were incubated in phosphate-free Krebbs buffer after extraction from the 
chest cavity at 37C.  One hundred microliters of H3PO4 was added to dilute a 1 µL aliquot of __ 
mCi H333P04.    All of the diluted radioactive phosphorous solution was added to the Krebbs 
buffer surrounding the aortas.  The mixture was allowed to incubate for ~3.5 hours, to allow for 
cell uptake and chemical exchange of 31P for the radioactive 33P.   All procedures were 
performed in designated radioactive work areas.   
 
Phorbol Incubation 
 Aortic tissue was incubated in 37°C Krebbs buffer.  Excess phorbol agonist was added to 
stimulate contraction—25 µL of 10-5 M phorbol in DMSO per ~2.5 mL Krebbs buffer.  Tissue 
was incubated ~0.5 hrs to facilitate a prolonged exposure to the contractile agonist. 
 
 
Cell Lysis 
PROCEDURE 1 
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 Cells were lysed in 0.5-1.0 mL, depending on amount of tissue, chilled lysis buffer with 
grinding to homogenize tissue.  Homogenate was then centrifuged at 12,000 RPM, ~12 min.  
The supernatant was collected as the aqueous protein extract.   
PROCEDURE 2 
 Cells were lysed in 0.5 mL chilled RIPA lysis buffer, containing phosphatase inhibitors, 
with grinding to homogenize tissue.  Homogenate was centrifuged at 12,000 RPM, ~12 min.  
The supernatant was collected as the aqueous protein extract, with lyophilization to concentrate, 
as necessary.  The pellet was saved for extraction of membrane proteins.   
 
Solubilization of Membrane Proteins 
PROCEDURE 1 
The pellet was boiled in 10% SDS to solubilize membrane proteins, ~10 min.  The 
supernatant was collected as the membrane protein extract. 
PROCEDURE 2 
The pellet was boiled in sample buffer I, 100°C for ~5 min.  The mixture was vortexed, and 
boiled again ~5 min.  The mixture was centrifuged 12,000 RPM, ~10 min.  The supernatant was 
collected as the membrane protein extract.   
PROCEDURE 3 
Genomic Solutions Protocol—The pellet was boiled in sample buffer I, 100°C for ~7 min.  
The mixture was then chilled on ice.  Fourty-five microliters of sample buffer II, containing 
RNAse and DNAse, were added.  The mixture was chilled on ice ~8 min with sonication.  Nine 
hundred microliters of acetone were added to produce an 80% v/v solution.  The mixture was 
chilled on ice ~20 min.  Then, the mixture was centrifuged at 10,000 RPM, ~15 min.  The 
supernatant was removed, and the pellet was allowed to dry.  The pellet was then redissolved in 
sample buffer mix. 
 PROCEDURE 4 
Sigma ProteoPrep Universal Extraction Reagent—One milliliter of soluble cytoplasmic 
protein reagent was added to the pellet.  The mixture was sonicated on ice, ~5 min, and then 
centrifuged at 4°C, 13,000 RPM for 45 min. The supernatant was collected as the aqueous 
membrane protein extract, which was then lyophilized to dryness, and redissolved in the soluble 
protein resuspension reagent.  The pellet was redissolved in 1 mL of the cellular and organelle 
 46
membrane solubilizing reagent, and warmed to room temperature.  The mixture was vortexed 
and sonicated, ~10 min, and then centrifuged at 13,000 RPM, ~45 min at 4°C.  The supernatant 
was collected as membrane protein extract.178  
 
II. Sample Purification 
 
Acetone Precipitation 
Ice cold acetone was added to the supernatant and to the pellet to solubilize and wash 
away unwanted contaminants, leaving a more pure protein precipitate.   The pellet was then 
redissolved in sample buffer mix, ready for gel electrophoresis. 
 
Dialysis 
 One hundred µL of sample mixture were loaded into a DisposoBiodialyzer unit from 
Harvard Biosciences.  Air bubbles were removed from the surface of the dialysis membrane as 
the unit was placed into the dialysis buffer.   Samples were dialyzed overnight in either dialysis 
buffer I or dialysis buffer II, with at least one change of buffer.   
 
III. Separation/Isolation of Proteins 
 
1D SDS-PAGE  
 A 1D gel apparatus from BioRad was used to facilitate 1D SDS-PAGE.  All parts of the 
apparatus should be sufficiently cleaned and rinsed with nanopure water. Samples were mixed in 
a 1:1 ratio with Laemmili Sample Buffer to reduce the sample.  Samples were then heated to 95º 
for approximately 3 minutes.  Tris/Glycine/SDS running buffer was added to the tank of the 
apparatus to serve as both the anode and cathode buffer.  Fifteen to twenty µL of the sample 
mixture was loaded into the well of the gel.  Every other well was used to avoid cross-
contamination of proteins during propagation through the gel.  Prestained MW standards from 
BioRad were loaded into the wells at each end of the gel.  Gels were subjected to 100 V for ~45-
90 minutess, or until the blue dye front reached the bottom of the gel.   
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 2D SDS-PAGE 
A 2D gel apparatus from Genomic Solutions was used to facilitate 2D SDS-PAGE.  All 
parts of the apparatus should be sufficiently cleaned and rinsed with nanopure water.  Eleven 
liters of freshly prepared of SDS-PAGE anode buffer was poured into the lower tank of the slab 
gel apparatus.  The cooling plate was turned on to allow the buffer to cool overnight. Three liters 
of freshly prepared SDS-PAGE cathode solution was refridgerated overnight, as well.   
 
1st Dimension Separation 
Tube Gel Procedure 
IEF anode buffer was poured into the tank of the IEF apparatus.  The tube gel apparatus 
was lowered into the tank.  One tube gel per sample was installed into the apparatus, with 
removal of air bubbles from both sides of the tube with a syringe filled with the appropriate 
anode or cathode solution.  Approximately 50 µL of sample overlay buffer was then loaded into 
each tube gel.  Samples were mixed 1:1 with sample buffer mix, if not already solubilized in this 
buffer.  Fifty µL of the sample mixture was loaded into the tube gel.   Eight hundred milliliters of 
IEF cathode buffer was poured into the upper chamber of the apparatus.  Gels were focused for 
17.5 hours at a maximum voltage of 2000 V and a maximum current of 110 µA per gel.       
Tube gels were placed on ice for ~10 minutes.  Tube gels were then extruded into ~2 mL 
of IEF equilibration buffer, and allowed to incubate for no more than 2 minutes.  Tube gels were 
loaded onto slab gels for second dimension separation. 
IPG Strip Procedure 
 Four hundred microliters of IPG urea/thiourea solubilization/rehydration buffer was 
added to the protein precipitate obtained from the acetone precipitation.  This mixture was 
distributed evenly between the electrodes of the pHaser tray.  IPG strips were placed gel-side 
down over top of the mixture, removing air bubbles from underneath the strip.  Tray was placed 
in a plastic bag with a piece of moistened filter to keep gels from drying out.  Samples were 
allowed to rehydrate for ~16 hours.   
 The pHaser tray was placed into the voltage housing unit.  The unit was set on top of a 
chiller.  A moistened wick was placed between the electrodes and the ends of the gel strips.  
Approximately two milliliters of mineral oil was spread over the top of the strip.  Strips were 
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focused for 24.5 hours with a maximum voltage of 5000 V and a maximum current of 80 µA per 
gel.  The temperature was maintained between 15-20 °C during focusing.  Wicks were replaced 
every hour for three hours to aid in the removal of salts.  
 IPG strips were placed in ~10 mL IPG equilibration buffer I and agitated for ~10 
minutes.  The buffer was discarded and this step was repeated.  The buffer was discarded and 
~10 mL of IPG equilibration buffer II was added to the tray.  The strips were agitated for ~10 
minutes.  Strips were removed from buffer and loaded onto slab gels for second dimension 
separation. 
  
2nd Dimension Separation 
 The 2D SDS PAGE anode and cathode buffers were previously chilled overnight.  The 
tank of the slab gel was filled with 11 L of 2D SDS PAGE anode buffer.  Grooves of slab gels 
(housing the tube gels or IPG strips) were filled with 2× 2D SDS PAGE cathode buffer.  Slab 
gels were loaded into the slab gel apparatus, securing grommets around slab gel to prevent 
leakage of solutions.  The slab gel apparatus was lowered into the tank.  The upper chamber of 
the apparatus was filled with three liters of 2D SDS PAGE cathode buffer.  A maximum of 500 
Volts was applied across the gel for approximately 4.5-5 hours, or until the blue dye front 
reached the bottom of the gel.  Gels were removed from cassettes and washed in nanopure water 
for 10 minutes with one change of water.   
 
 
 
 
 
 
IV. Analysis 
 
Visualization of Protein Bands 
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Autoradiography 
 2D gel with proteins was wrapped in plastic wrap and placed into an autoradiography 
cassette.  In the dark, a piece of XOMAT-AR film paper was placed on top of the gel.  The 
cassette was closed and sealed that no light could get into the cassette.  Gels were exposed for 12 
hours for the first trial, and then 36 hours for the second trial.   
 
Gel Staining 
GelCode Blue Protein Stain 
 One dimension protein gels were agitated in GelCode Blue protein stain for three hours.  
The solution was removed.  Gels were then agitated in nanopure water to reduced background 
staining.  Gels were imaged with a visible light source.   
Phosphoprotein Stain 
 Gels were agitated in ~500 mL of phosphoprotein fixing solution for one hour with one 
change of fixing solution.  The solution was removed.  Gels were then washed with ~500 mL of 
nanopure water for ~15 minutes to remove the methanol and acetic acid from the gel.  This step 
was repeated three times.  Gels were agitated in 500 mL of ProQ Diamond Phosphoprotein Gel 
Stain in the dark for four hours.  The solution was removed, and gels were agitated in 
phosphoprotein destain solution in the dark for a total of four hours with three changes of destain 
solution.  Gels were imaged with a visual source.   
Coomassie Brilliant Blue Protein Stain 
 Gels were agitated in ~500 mL of Coomassie fixing/destain solution for one hour to fix 
proteins to gel and remove any remaining SDS from the gel.  The solution was discarded.  Gels 
were then agitated in ~500 mL of Coomassie Brilliant Blue stain overnight.  The solution was 
removed, and ~500 mL of Coomassie fixing/destain was added.  Gels were agitated in destain 
for one hour.  The destaining step was repeated up to four times to remove enough background 
stain for protein bands to be effectively visualized.  Gels were imaged with a visual light source.   
SYPRO Ruby Protein Gel Stain 
 Gels were agitated in ~500 mL of Ruby fixing/destain solution for 30 minutes.  The 
solution was removed.  Gels were then agitated in ~500 mL SYPRO Ruby protein gel stain 
overnight.  The solution was discarded, and gels were agitated in ~500 mL of SYPRO Ruby 
fixing destain solution for 30 minutes.  Gels were imaged with a UV light source. 
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Silver Stain 
 Gels were agitated in ~800 mL of silver fixing solution for 30 minutes.  The solution was 
removed.  Gels were then washed with nanopure water for 20 minutes with agitation.  This step 
was repeated.  The silver stain was prepared fresh immediately prior to use, and gels were 
agitated in stain for ~20 minutes, or until protein bands were effectively visualized.  The solution 
was removed, and the silver stop solution was added immediately.  Gels were imaged with a 
visual light source. 
 
Gel Imaging 
 
Gels were imaged and analyzed using either the BioRad GelDoc Imager or the Genomic 
Solutions ProPic Investigator Imager.  Either a visible or UV light source was used to image the 
gels, according to that required by the excitation/emission wavelength of the method of staining.  
 
Proteolytic Digest of Proteins—In Gels (Tryptic Digest) 
 
 Protein bands were excised from the gel either by hand for manual excision or by the 
Genomic Solutions ProPic Investigator for automatic excision.  For silver stained gels, excised 
bands were incubated in silver destain solution for 30 minutes.  This solution was then removed 
and bands were washed three times with nanopure water for a total of 30 minutes, 10 minutes 
between changes of water.   
Gel bands were incubated in AcCN for 10 minutes to destain and/or dehydrate gel pieces.  
Gel bands were then lyophilized in a SpeedVac to remove the AcCN.  A reducing buffer of 10 
mM DTT in 100 mM NH4HCO3 was added to the gel pieces, which were then incubated for one 
hour at 56°C.   
The solution was discarded and gel bands were allowed to cool to room temperature.  A 
modification buffer of 55 mM iodoacetamide in 100 NH4HCO3 was added to the gel pieces, 
which were then incubated at room temperature in the dark for ~45 minutes.   
The solution was discarded and gel pieces were washed with 100 mM NH4HCO3 for 20 
minutes.  This solution was discarded and gel pieces were dehydrated with AcCN.  The AcCN 
was removed.  These steps were repeated.  Gel pieces were then lyophilized to remove all AcCN.  
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Twenty microliters of a 2 µg/mL (pH 8.5) solution of modified trypsin in 40 mM NH4HCO3 was 
added to the gel pieces.  The trypsin was allowed to digest the proteins overnight at 37°C to 
cleave the protein at arginine and lysine amino acid residues.  
The supernatant was collected.  Peptide fragments were extracted with one change of 20 
mM NH4HCO3 and three changes of 5% formic acid in 50% AcCN.  All washes were collected, 
and the solution was lyophilized in a SpeedVac to necessary volumes. 
 
Desalting 
 
Reverse Phase HPLC 
 Fifty microliters of the sample was loaded into the HPLC injection port.  For protein 
samples, a C-4 column was used, and for peptide samples, a C-18 column was used.  Samples 
were passed over the appropriate column.  Salts and contaminants were washed through the 
column with 0.1% AcOH.  Proteins/peptides were eluted off the column with a gradient increase 
of 70% AcCN in 0.085% AcOH.  A UV/Visible wavelength spectroscopic detector set at 214 nm 
was used to detect the amine groups of the proteins/peptides.  The eluant was lyophilized in a 
SpeedVac to approximately two microliters in preparation for MALDI-TOF MS.  If samples 
were lyophilized to dryness, they were redissolved in 5% formic acid in 50% AcCN.   
 
Ziptip desalting 
 Samples were previously concentrated to 10 µL of volume, or were redissolved in 10 µL 
of 0.1% TFA if dry.  A ziptip was attached to an eppendorf pipette.  For proteins, a C-4 packed 
tip was used, and for peptides, a C-18 packed tip was used.  The ziptip was wetted by aspirating 
10 µL of wetting solution.  The ziptip was then equilibrated by aspirating 10 µL of 
equilibration/wash solution.  Proteins/peptides were bound to the beads of the tip by aspirating 
the sample mixture for 10-15 cycles.  The sample was washed by aspirating 10 µL of 
equilibration/wash solution three times.  Proteins/peptides were eluted with 20 µL of elution 
solution, followed by a third exctraction of 100% AcCN to remove all proteins/peptides from the 
tip.  The eluant was lyophilized in a SpeedVac to approximately two microliters in preparation 
for MALDI-TOF MS.  If samples were lyophilized to dryness, they were redissolved in 5% 
formic acid in 50% AcCN.   
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MALDI-TOF Analysis 
 
Spotting   
Samples were spotted using the two layer method of spotting to ensure homogenous spots 
of samples.  A volume of 0.7 µL of the first layer solution was spotted onto the MALDI probe to 
create a homogenous layer of matrix.  The volatile solvent assures fast evaporation.  
Concentrated and desalted samples were mixed 1:1 with the second layer solution, with 
aspiration to mix.  A volume of 0.7 µL of this mixture was spotted on top of the dried first layer.  
This layer was allowed to dry before the MALDI probe was inserted into the instrument.   
 
Calibration 
External Calibration 
A Bruker Biflex III MALDI-TOF MS was used for analysis in this investigation.  The 
instrument was calibrated in the peptide fingerprint range using a sample of peptide standards of 
known m/z value.  The standards were stored in a solution of 0.1% TFA, and spotted on the 
MALDI probe according to the procedure outlined above.  A linear calibration was performed 
using the monoisotopic m/z values of the standards listed in table 2.   
External calibration was performed immediately preceding acquisition of data for sample 
analysis.  It is important that a calibration be performed if any of the parameters of the 
instrument are changed—voltage, laser power, etc.—prior to acquisition of data.   
 
 
Calibration Standards 
Peptide Standard M/Z Value 
Angiotensin II 1046.542 
Angiotensin I 1296.685 
Substance P 1347.736 
Bombesin 1619.823 
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ACTH clip 1-17 2093.086 
ACTH clip 18-39 2465.199 
Somatostatin-28 3147.47 
Table 2:  List of the peptide standards and corresponding m/z peak values used for external and internal calibration 
of MALDI spectra. 
 
Internal Calibration 
 An aliquot of the sample mixture was spotted on the MALDI probe as outlined above.  
One microliter of a 1/20 dilution of the peptide standards from table 2 was added to the 
sample:matrix solution , with aspiration to mix.  This mixture was then spotted as the second 
layer in the spotting method outlined above.   
 A suitable spectrum was collected for each spot.  The spectrum containing the standards 
was calibrated using the correct m/z values for the standard peaks.   Then, three to four sample 
peaks that spanned a range representative of the sample spectrum were selected to calibrate the 
spectrum from the sample.  These peaks were matched to their corresponding peaks in the 
uncalibrated spectrum, and used to calibrate this spectrum.   
 
Data Acquisition 
 Samples were analyzed on a Bruker Biflex III MALDI-TOF MS.  Analysis was 
performed in reflectron mode (see Appendix II) in the range of 500 to 4000 Da.  The delayed 
extraction time period was set to medium.  Preliminary data from a sample spot was collected to 
fine tune the attenuation of the laser power and IST voltages of the instrument to a level which 
provided the best spectrum.  The instrument was then calibrated externally under these 
parameters.   
 The sample spot was searched for an area which gave the highest S/N ratio peaks.  Then 
an averaged spectrum of ~100 laser shots was collected.  This was done for each sample to 
provide digest (peptide fingerprint) spectra for each. 
 
Post Source Decay (PSD) 
 The instrument was externally calibrated according to the procedure outlined above.   A 
standard sample spot of ACTH clip 18-39 was used to calibrate the instrument.  The ion gate was 
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set to the m/z value for the standard to deflect unwanted particles (see Appendix II).  A suitable 
spectrum was collected for each mass range afforded by the KE filter.  Various parameters were 
manipulated—deflection time, IS/T voltages, laser power—to optimize the conditions of the 
instrument to provide the best spectra.  The series of pre-pasted spectra were collected for the 
standard, and then compared by the instrument to the known m/z fragmentation values of the 
standard.  The instrument was calibrated in this manner to produce the final calibrated 
fragmentation spectrum.    
 The m/z of the peptide to be analyzed was set in the ion gate.  The sample spectra were 
collected in the same way as the standard.  Data was acquired under the same parameters as the 
standard to maintain calibration.     
 
Identification of Unknown Proteins/Protein Database Searching (MASCOT) 
  
Peptide fingerprints of proteins were matched to those found in online protein databases 
using the MASCOT search engine from Matrix Science of London237, using the specifications 
listed in table 3, below. 
 
Missed 
Cleavages 
Cystine 
Modifications 
Methionine 
Modifications 
M/Z Mass 
Range 
Taxonomy 
Up to 2 Carbamidomethyl 
(Acetamide) 
Oxidized 2 Da Rodentia 
Table 3:  List of the specifications entered into the search form of the MASCOT search engine protein database. 
 
 Contaminating trypsin peaks were first eliminated from the peak list.  Trypsin peaks were 
determined from a peptide fingerprint map of a theoretically digested trypsin protein with 
dimethylated lysines and oxidized methionines and/or from a self-digested mixture of trypsin 
and a blank piece of gel, as performed in the laboratory at Marshall University.   
 Once the matching fingerprints were identified using MASCOT, likely protein candidates 
were produced by the database search engine.  The peptide fingerprint of the smooth muscle 
isoform of the putative protein, if available, may have been compared manually to the sample’s 
spectra to look for possible phosphorylation sites or other modifications, assuming the putative 
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protein produced was within the correct molecular weight range estimated from the position of 
the protein band on the 2D gel and the score of the putative match is significant.   
The search engine matches peaks and uses a probability function to provide a score.  The 
score is a representation of the probability that a correct match has been obtained, (equation __). 
 
MASCOT score = -10 log P            (19) 
 
where P = the probability that the match could occur randomly in nature.  Only those candidates 
with significant scores (>56) were reported in the results section of this work. 
 The website search engine also provides a percentage of the protein’s amino acid peptide 
fragment sequence covered by the m/z peak list entered into the database.   
 
 
 
 
 
 
 
 
 
 
RESULTS AND DISCUSSION 
 
The primary objective of this work focused on the analysis of differential protein 
phosphorylation between resting and contracted aortic SM tissue using proteomic techniques and 
MALDI-TOF mass spectrometry.  It was hoped that this versatile technique coupled with the 
application of protein database information would help clarify the signal transduction pathways 
at work in smooth muscle tissue.  However, many challenges were encountered in pursuit of this 
goal, so that the body of this discussion focuses, instead, on the development of protocol for the 
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analysis of phosphoproteins.  Many problems have been investigated and resolved, while some 
difficulties remain.  These difficulties limit the scope of this research.   
 
2D Gel Electrophoresis  
 
The quantity of proteins separated and visualized on a 2D gel using tube gel IEF focusing 
was found to be too low to allow adequate sample analysis.  A tube gel apparatus was initially 
used to focus proteins based on their pI in the first dimension separation of the 2D 
electrophoresis.  The maximum quantity of protein that may be loaded into the tube gel is 100 
µg, dissolved in 50 µL of buffer.  The 2D gels obtained by this method had to be stained with the 
more sensitive stains, such as silver stain or SYPRO ruby stain with a limit of detection near 1 
ng, to allow any type of visualization.  Staining with the colloidal Coomassie blue stain (limit of 
detection—1 µg) proved to be insufficient. 
Some gels showed very little visualization of protein bands even with such sensitive 
stains.  Figures 22-32 depict gels stained with the more sensitive silver stain and SYPRO ruby 
protein gel stain.  A considerable amount of nonspecific or artifact staining (blots of stain that do 
not represent protein bands) can be seen on those gels stained with silver stain.   
 
 
 
 
 
2D_7_24_01_Phorbol_sup 
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Figure 22:  Example of a 2D gel containing supernatant or aqueous proteins from phorbol-contracted 
aortic SM tissue stained with silver stain, revealing very little evidence of protein bands. 
 
 
2D_7_30_02_Control 
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Figure 23:  Example of a 2D gel containing supernatant or aqueous proteins from resting aortic SM tissue 
stained with silver stain, revealing very little evidence of protein bands. 
 
 
2D_10_09_02_Control 
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Figure 24:  Example of a 2D gel containing supernatant or aqueous proteins from resting aortic SM tissue 
treated with RNAse and DNAse prior to electrophoresis.  This gel was stained with silver stain, and reveals very 
little evidence of protein bands. 
 
2D_10_09_02_Phorbol 
 
Figure 25:  Example of a 2D gel containing supernatant or aqueous proteins from phorbol-contracted 
aortic SM tissue treated with RNAse and DNAse prior to electrophoresis.  This gel was stained with silver stain, and 
reveals very little evidence of protein bands. 
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2D_10_09_02_Control_Pell 
 
 
Figure 26:  Example of a 2D gel containing membrane proteins from resting SM tissue, where proteins 
were solubilized in boiling 10% SDS and treated with RNAse and DNAse prior to electrophoresis.  This gel was 
stained with silver stain, and reveals very little evidence of protein bands. 
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2D_10_09_02_Phorbol_Pell 
 
Figure 27:  Example of a 2D gel containing membrane proteins from phorbol-contracted SM tissue, where 
proteins were solubilized in boiling 10% SDS and treated with RNAse and DNAse prior to electrophoresis.  This 
gel was stained with silver stain, and reveals very little evidence of protein bands. 
 
2D_6_18_02_Control 
 
 
 
Figure 28:  Example of a 2D gel containing supernatant or aqueous proteins from resting aortic SM tissue 
stained with SYPRO ruby protein gel stain, revealing very little evidence of protein bands. 
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2D_6_18_02_Phorbol 
 
Figure 29:  Example of a 2D gel containing supernatant or aqueous proteins from phorbol-contracted 
aortic SM tissue stained with SYPRO ruby protein gel stain, revealing very little evidence of protein bands. 
 
2D_7_12_02_Control 
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Figure 30:  Example of a 2D gel containing supernatant or aqueous proteins from resting aortic SM tissue 
stained with SYPRO ruby protein gel stain, revealing very little evidence of protein bands. 
 
 
2D_7_12_02_Phorbol 
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Figure 31:  Example of a 2D gel containing supernatant or aqueous proteins from phorbol-contracted 
aortic SM tissue stained with SYPRO ruby protein gel stain, revealing very little evidence of protein bands. 
 
2D_7_30_02_Phorbol 
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Figure 32:  Example of a 2D gel containing supernatant or aqueous proteins from resting aortic SM tissue 
stained with silver stain. 
 
 
 
Overall, silver staining provided the best visualization of protein bands.  However, 
because of the low quantity of protein per band, limited success was achieved for analysis by 
tryptic digest and subsequent MS analysis.  Many of the averaged digest spectra obtained from 
these gels were of poor signal to noise (S/N) ratio.  Examples of these types of digest spectra can 
be seen in figures 33-45, below.  The location of the digested bands on the corresponding 2D gel 
may be seen in the figures, above.   
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Figure 33:  Example of an averaged tryptic digest spectrum obtained from protein band 8C the gel 2D_7_30_02 
Control, revealing low S/N ratios for peptide peaks.   
 
Figure 34:  Example of an averaged tryptic digest spectrum obtained from protein band 4P the gel 2D_7_30_02 
Phorbol, revealing low S/N ratios for peptide peaks.   
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Figure 35:  Example of an averaged tryptic digest spectrum obtained from protein band 5C the gel 2D_7_30_02 
Control, revealing low S/N ratios for peptide peaks.   
 
Figure 36:  Example of an averaged tryptic digest spectrum obtained from protein band 2P the gel 2D_7_30_02 
Phorbol, revealing low S/N ratios for peptide peaks.   
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Figure 37:  Example of an averaged tryptic digest spectrum obtained from protein band 2C on the gel 2D_7_12_02 
Control, revealing low S/N ratios for peptide peaks.   
 
Figure 38:  Example of an averaged tryptic digest spectrum obtained from protein band 3C on the gel 2D_7_12_02 
Control, revealing low S/N ratios for peptide peaks.   
 69
 
Figure 39:  Example of an averaged tryptic digest spectrum obtained from protein band 1P on the gel 2D_7_12_02 
Phorbol, revealing low S/N ratios for peptide peaks.   
 
Figure 40:  Example of an averaged tryptic digest spectrum obtained from protein band 2Pon the gel 2D_7_12_02 
Phorbol, revealing low S/N ratios for peptide peaks.   
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Figure 41:  Example of an averaged tryptic digest spectrum obtained from protein band 18C on the gel 
2D_10_09_02_Control, revealing low S/N ratios for peptide peaks.   
 
 
Figure 42:  Example of an averaged tryptic digest spectrum obtained from protein band 24C on the gel 
2D_10_09_02_Control, revealing low S/N ratios for peptide peaks.   
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Figure 43:  Example of an averaged tryptic digest spectrum obtained from protein band 15P on the gel 
2D_7_30_02_Phorbol, revealing low S/N ratios for peptide peaks.   
 
Figure 44:  Example of an averaged tryptic digest spectrum obtained from protein band 7CP on the gel 
2D_10_09_02_Control_Pell, revealing low S/N ratios for peptide peaks.   
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Figure 45:  Example of an averaged tryptic digest spectrum obtained from protein band 6CP on the gel 
2D_10_09_02_Control_Pell, revealing low S/N ratios for peptide peaks.   
 
 
Because of such difficulties, the focus of the research was simplified to mapping the 
proteome through identification of proteins on the gel in resting SM tissue in attempt to confirm 
the protocol.    
Other explanations for the production of inadequate gels have been investigated.  Poor 
solubilization of proteins was suggested as one possible explanation for this phenomenon.  Many 
different methods of protein solubilization were attempted with little improvement of protein 
band intensity and subsequent data acquisition.    
The cellular extract was first boiled in 10% SDS to help denature and solubilize all 
proteins.  Protein concentration was not high enough for visualization with Coomassie, and had 
to be stained with silver stain (Figure 46).  Though bands were visualized for this method, no 
identifications were made from the data collected for this gel.   
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2D_7_12_01_Phorbol_pell  
 
Figure 46:  Example of a 2D gel containing membrane proteins solubilized with boiling in 10% SDS, from 
phorbol-contracted aortic SM tissue stained with silver stain. 
 
 
 
At one point, it was believed that too much cellular debris (RNA, DNA, etc.) existed in the 
sample mixture to allow adequate migration within the tube gel, even though a chelating agent 
(EDTA) was added to the lysis buffer to chelate the negatively charged DNA/RNA in the 
sample.  Samples were treated with RNAse and DNAse enzymes prior to separation, but this did 
not appear to improve sample migration (Figures 24-27).   
It was also proposed that too much salt in the sample mixture prevented efficient IEF 
separation in the tube gels.  Therefore, samples were thoroughly dialyzed prior to separation to 
remove salt contamination.  Salts are naturally present in biological samples, and they may also 
have been introduced to the sample during cell lysis (RIPA buffer) or when tissue was incubated 
in salt-containing buffers (Krebbs buffer, PBS).  Samples were dialyzed for extended periods of 
time—overnight—with several changes of different dialysis buffers, both a low salt dialysis 
buffer (dialysis buffer I) and nanopure water.  Dialyzed samples were always lyophilized prior to 
1st dimension separation to concentrate the protein, as well.  However, 2D gels with adequate 
protein concentration were never obtained (Figures 24-32).   Finally, protein extracts were 
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submitted to acetone precipitation to remove salt/detergent contaminates and other cellular 
debris to purify the protein extract prior to electrophoresis (Figures 51 and 52).   
It was concluded that tube gel separation did not allow an adequate amount of protein to 
pass into the tube gel, and thus inhibited proper 2D gel sample analysis.  The tube gel holds only 
50 µL of solubilized protein.  Despite several attempts to concentrate and remove salt 
interference, little improvement was ever observed.   
To further support this conclusion, sample extracts of both the contracted and 
uncontracted tissue were run on a 1D gel to facilitate analysis (Figure 47).  From this gel, the 
presence of actin and tropomyosin were detected.   Band 1C was found to be tropomyosin with a 
MASCOT score of 63.  The placement of the band on the gel agrees with the MW of 
tropomyosin (~33 kDa).  Band 2C and 2P were identified as actin with MASCOT scores of 107 
and 81, respectively.   Their approximate MW on the gel also agrees with that of actin (~42 
kDA).  The digest spectra, peak lists, and MASCOT analysis data can be seen below (Figures 
48-50, Table 4).   No further identifications were made from this gel.   
 
Figure 47:  1D gel stained with Coomassie Brilliant Blue protein stain, depicting the location of excised bands 1C, 
2C, and 2P submitted to tryptic digest and MS analysis for successful identification.  Control-SuP = resting aortic 
SM tissue.  Phorbol-Sup = phorbol-contracted aortic SM tissue. 
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Figure 48:  Tryptic digest spectra and generated peak list of excised protein band 1C from the gel 1D-6-13-02, 
above.  This peak list was searched in MASCOT, which identified it as tropomyosin with a score of 63. 
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Figure 49:  Tryptic digest spectra and generated peak list of excised protein band 2C from the gel 1D-6-13-02, 
above.  This peak list was searched in MASCOT, which identified it as actin with a score of 107. 
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Figure 50:  Tryptic digest spectra and generated peak list of excised protein band 2P from the gel 1D-6-13-02, 
above.  This peak list was searched in MASCOT, which identified it as tropomyosin with a score of 81. 
 
MASCOT Search Results 
 
Gel Protein 
Band 
Identification MASCOT 
Score 
Sequence 
coverage 
Mass 
(kDa) 
pI 
1D-6-13-02 1C Tropomyosin 63 52% ~33 4.6 
1D-6-13-02 2C Actin 107 73% ~42 5.2 
1D-6-13-02 2P Actin 81 59% ~42 5.2 
 
Table 4:  List of the MASCOT search results for protein bands digested with trypsin from the 1D gel 6_18_02.  
Digest mixtures were analyzed with MALDI-TOF MS and searched in a protein database using the MASCOT 
search engine. 
 
 
IPG strips, which allow an upper limit of 1 mg of protein dissolved in 1 mL of buffer, 
were then used for IEF separation to improve protein band intensities.  The 2D gels obtained 
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from this technique were considerably more concentrated, and could be stained with Coomassie 
Brilliant Blue stain (Figures 49-50).   
 
2D_9_26_03_Control 
 
 
 
 
Figure 51:  Example of a 2D gel containing membrane proteins from resting aortic SM tissue solubilized 
with boiling in 10% SDS, and later purified via acetone precipitation.  The protein quantity in the bands of this gel 
was high enough to be visualized by Coomassie Brillaint Blue staining. 
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2D_9_26_03_Phorbol 
 
 
 
Figure 52:  Example of a 2D gel containing membrane proteins from phorbol-contracted aortic SM tissue 
solubilized with boiling in 10% SDS, and later purified via acetone precipitation.  The protein quantity in the bands 
of this gel was high enough to be visualized by Coomassie Brillaint Blue staining. 
 
It has also been observed that few low molecular weight proteins exist on the 2D gels.  
This may be because low MW proteins either migrated off the 2nd dimension slab gel due to 
over-extended running times or because they migrated out of the tube gel during equilibration of 
the tube gels in methylene blue.  The second explanation is more likely, because it is not 
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believed that the second dimension separation time was too long.  Applied voltages were stopped 
before the line of methlyene blue dye migrated off the gel, after approximately 4.5 to 5.0 hours.  
The MW of methylene blue is 319.85 Da, much smaller than the MW of proteins expected to be 
in biological samples.   
Once a gel of adequate protein level—that able to be detected by Coomassie staining—
was produced, then phosphoprotein detection and protein identification through MS analysis 
could be conducted.  In the future, it is recommended that a Bradford Protein Assay—to 
determine the concentration of protein—be conducted prior to electrophoresis to assure that 
equal amounts of total protein from the contracted and uncontracted tissue are used.   
 
MALDI-TOF MS Analysis 
 
 Low S/N ratios of peaks made MS analysis difficult.  Such poor quality spectra are partly 
explained by the low concentration of protein on the gels produced for tube gel IEF separation.  
Examples of such spectra may be seen in figures 32-46, above.  Once the problem of low protein 
abundance in gel plugs was solved by using IPG strips in the 1st dimension separation of 2D 
SDS-PAGE, another problem was discovered in MS analysis.  The instrument did not appear to 
hold calibration.  M/z values shifted irregularly over time.  MS spectra provided by the 
instrument used in this research proved to be ambiguous and not reproducible, which would 
largely explain the lack of sufficient results.  Parameters for the LASER attenuation and 
extraction voltages were not changed, and are not the source of ambiguity.   
Equilibration of the acceleration voltage, delayed extraction voltages, and/or reflectron 
voltages was targeted as an initial source of error.  Deviation in these voltages from the set 
voltage will result in deviant computations of m/z (see Appendix I).  The voltages were checked 
with a voltmeter and did not deviate from the set values.  However, approximately 15 minutes 
was allowed for equilibration of the high voltages prior to acquisition of data.  This did not solve 
the problem.   
Improportional depth of the target probe has also been proposed as a source of error.  
Slight deviations in the depth of analyte within the ionization chamber can cause differences in 
the distance traveled by the ions, and subsequent deviations in computed m/z values.  Methods to 
combat inhomogeneity on the surface of the probe, such as the two-layer method of spotting, 
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were always applied.  In this method, a homogenous layer of matrix is spotted using a volatile 
solvent, and the matrix-embedded sample is spotted on top of this layer to create a homogenous 
surface layer of analyte.  The purchase of a new probe may also aid in this problem.  It is 
possible that the probe may have been damaged due to mishandling and may not be even.  This 
has not yet been tried. 
The application of an internal standard was then utilized to combat this problem, with 
limited success.  For this application a diluted extract of peptide standards was added to a 
fraction of the sample mixture, which was then spotted on the MALDI probe.  The acquired 
spectrum containing the internal standards was calibrated.  Abundant sample peptide peaks were 
chosen as calibrants for the spectrum containing only peaks from the sample mixture—no 
internal standards.  Using this methodology, the localization of some proteins on the 2D gel were 
discovered, including actin, tropomyosin, and MHC.  The data supporting these conclusions may 
be seen in figures 53-63 and table 5, below.   
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Figure 53:  Tryptic digest spectra and generated peak list of excised protein band 1C from the gel 
2D_10_9_02_Control.  This peak list was searched in MASCOT, which identified it as tropomyosin with a score of 
278. 
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Figure 54:  Tryptic digest spectra and generated peak list of excised protein band 4C from the gel 
2D_10_9_02_Control.  This peak list was searched in MASCOT, which identified it as tropomyosin with a score of 
88.  
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Figure 55:  Tryptic digest spectra and generated peak list of excised protein band 6C from the gel 
2D_10_09_02_Control.  This peak list was searched in MASCOT, which identified it as tropomyosin with a score 
of 112. 
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Figure 57:  Tryptic digest spectra and generated peak list of excised protein band 8C from the gel 
2D_10_09_02_Control.  This peak list was searched in MASCOT, which identified it as actin with a score of 108. 
  
 
 920.324  1241.279 
 974.206  1244.351 
 975.274  1259.189 
1036.816  1265.274 
1046.820  1277.248 
1049.818  1300.071 
1066.734  1307.194 
1090.633  1316.213 
1107.614  1365.089 
1122.622  1366.149 
1135.490  1379.170 
1141.479  1383.087 
1165.432  1391.138 
1179.423  1407.102 
1184.392  1427.195 
1194.396  1431.133 
1201.426  1434.144 
1203.330  1458.091 
1206.344  1475.101 
1222.311  1487.100 
1223.462  1493.016 
1234.342 
 
 
 
 
 
 
 
Figure 58:  Tryptic digest spectra and generated peak list of excised protein band 12C from the gel 
2D_10_09_02_Control.  This peak list was searched in MASCOT, which identified it as MHC with a score of 86. 
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1476.287 
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1547.740 
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1213.771 
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Figure 59:  Tryptic digest spectra and generated peak list of excised protein band 11P from the gel 
2D_7_30_02_Phorbol.  This peak list was searched in MASCOT, which identified it as tropomyosin with a score of 
74. 
 
 856.228  2215.275 
 
 876.077  2229.358 
 892.011  2232.355 
 975.676  2248.528 
1045.051  2389.008 
1130.303  2512.835 
1140.388  2528.920 
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1355.094 
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1537.064 
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1807.238 
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1879.648 
1883.679 
1957.012 
1959.006 
1987.086 
 
 
 
 
Figure 60:  Tryptic digest spectra and generated peak list of excised protein band 1C from the gel 2D_7_12_02 
_Control.  This 
peak list was 
searched in 
MASCOT, which 
identified it as 
tropomyosin with 
a score of 59. 
 1045.136 
1065.838 
1081.691 
1097.643 
1150.498 
1197.721 
1201.743 
1267.993 
1299.093 
1490.064 
1537.327 
1730.038 
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1792.239 
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2524.225 
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Figure 61:  Tryptic digest spectra and generated peak list of excised protein band 5P from the gel 2D_7_12_02 
_Phorbol.  This peak list was searched in MASCOT, which identified it as MHC with a score of 61. 
 
 
 
 
 
 
MASCOT Search Results 
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Gel Protein Identification MASCOT Sequence Mass pI 
Band Score coverage (kDa) 
10_09_02_Control 1C Tropomyosin 278 73% ~33 4.6 
10_09_02_Control 4C Tropomyosin 88 47% ~33 4.6 
10_09_02_Control 6C Tropomyosin 112 43% ~33 4.6 
10_09_02_Control 8C Actin 108 45% ~42 5.2 
10_09_02_Control 12C MHC 86 44% ~150-
250 
-- 
10_09_02_Phorbol 11P Tropomyosin  74 40% ~33 4.6 
7_12_02_Control 1C Tropomyosin 59 34% ~33 4.6 
7_12_02_Phorbol 5P MHC 61 56% ~150-
250 
-- 
 
Table 5:  List of the MASCOT search results for protein bands digested with trypsin that were successfully 
identified with the aid of internal standards from various gels (as designated in the figures, above).  Digest mixtures 
were analyzed with MALDI-TOF MS and searched in a protein database using the MASCOT search engine. 
 
 
 
 
The acquisition of quality spectra for both the sample spot and the sample with standards 
spot was difficult, given the already low S/N ratios of peaks.  The same problem of low protein 
quantity described before contributed to the lack of adequate spectra.  This trend hindered the 
ability to calibrate the spectra using this method.   
  The application of an internal standard within sample mixtures helped to demonstrate 
the inconsistencies encountered during operation of the MALDI-TOF instrument.  The following 
spectra were acquired chronologically as they are listed in the text.  The correct m/z values for 
the internal standards used are listed in table 2.  The shift in the reported m/z values 
corresponding to these standards can be seen in the spectra, below. 
The first three spectra are from the same sample spot (Figures 62-64).  The standard 
peaks first shift down in m/z and then shift back up without changing any parameters, though the 
position on the spot where the LASER was fired was changed.   
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Figure 62:  Tryptic digest from band 10P from the gel 2D_9_26_03_Phorbol.  The uncalibrated m/z peaks for the 
standards substance P, bombesin, and ACTH clip 18-39 can be seen.  When compared to the other spectra of this 
same spot (Figures 61 and 62), the shifts in the m/z values can be seen. 
 
Figure 63:  Tryptic digest from band 10P from the gel 2D_9_26_03_Phorbol.  The uncalibrated m/z peaks for the 
standards substance P, bombesin, and ACTH clip 18-39 can be seen.  When compared to the other spectra of this 
same spot (Figures 60 and 62), the shifts in the m/z values can be seen. 
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Figure 64:  Tryptic digest from band 10P from the gel 2D_9_26_03_Phorbol.  The uncalibrated m/z peaks for the 
standards substance P, bombesin, and ACTH clip 18-39 can be seen.  When compared to the other spectra of this 
same spot (Figures 60 and 62), the shifts in the m/z values can be seen. 
 
 
 
The following four spectra all contain standard peaks (Figures 65-68).  They are from different 
sample spots acquired on the same day, listed chronologically in time.  Again, none of the 
parameters of the instrument were changed.  The ambiguity of the m/z values reported for the 
standard peaks can be seen.   
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Figure 65:  Tryptic digest from band 1P from the gel 2D_9_26_03_Phorbol.  The uncalibrated m/z peaks for the 
standards substance P, bombesin, ACTH clip 18-39, and Somatostatin-28 can be seen.  When compared to the other 
spectra acquired on the same day under the same instrumental parameters (Figures 65-68), the shifts in the m/z 
values can be seen. 
 
 
Figure 66:  Tryptic digest from band 4P from the gel 2D_9_26_03_Phorbol.  The uncalibrated m/z peaks for the 
standards substance P, bombesin, ACTH clip 18-39, and Somatostatin-28 can be seen.  When compared to the other 
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spectra acquired on the same day under the same instrumental parameters (Figures 65,67-68), the shifts in the m/z 
values can be seen. 
 
 
 
 
 
 
Figure 67:  Tryptic digest from band 6P from the gel 2D_9_26_03_Phorbol.  The uncalibrated m/z peaks for the 
standards substance P, bombesin, ACTH clip 18-39, and Somatostatin-28 can be seen.  When compared to the other 
spectra acquired on the same day under the same instrumental parameters (Figures 65-66, 68), the shifts in the m/z 
values can be seen. 
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Figure 68:  Tryptic digest from band 2P from the gel 2D_9_26_03_Phorbol.  The uncalibrated m/z peaks for the 
standards substance P, bombesin, ACTH clip 18-39, and Somatostatin-28 can be seen.  When compared to the other 
spectra acquired on the same day under the same instrumental parameters (Figures 65-67), the shifts in the m/z 
values can be seen. 
 
Many adequate digest spectra, with a sufficient number of suitable S/N ratio peaks, were 
produced that could not be identified when peak lists were searched in the protein database.  
Some of these spectra can be seen in figures 69-74.  Unfortunately, many protein candidates 
were found for each peptide fingerprint entered into the protein database search.  Different 
search engines were used to determine whether the search engine was to blame for the lack of 
results.  The same ambiguous results were furnished by the search engines.  No two search 
engines produced the same results, either.   
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Figure 69:  Example of a tryptic digest of band 14C from the gel 2D_7_30_02_Control.  The spectrum has a 
sufficient number of adequate S/N peaks, but no identification could be made in the protein database. 
 
Figure 70:  Example of a tryptic digest of band 11P from the gel 2D_7_30_02_Phorbol.  The spectrum has a 
sufficient number of adequate S/N peaks, but no identification could be made in the protein database. 
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Figure 71:  Example of a tryptic digest of band 16C from the gel 2D_10_09_02_Control.  The spectrum 
has a sufficient number of adequate S/N peaks, but no identification could be made in the protein database.  This 
spectrum was calibrated with internal standards, as well. 
 
Figure 72:  Example of a tryptic digest of band 26C from the gel 2D_10_09_02_Control.  The spectrum 
has a sufficient number of adequate S/N peaks, but no identification could be made in the protein database. 
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Figure 73:  Example of a tryptic digest of band 9CP from the gel 2D_10_09_02_Control_Pell.  The 
spectrum has a sufficient number of adequate S/N peaks, but no identification could be made in the protein 
database. 
 
Figure 74:  Example of a tryptic digest of band 17C from the gel 2D_10_09_02_Control.  The spectrum 
has a sufficient number of adequate S/N peaks, but no identification could be made in the protein database. 
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A sufficient explanation as to why the instrument provides irregularly shifted m/z values 
has yet to be determined.  Unintentional venting of the vacuum chambers may have allowed 
accumulation of water vapor, gases, dust, or other contaminants that would collide/interfere with 
the propogation of ions down the flight tube.  Normal internal corrosion of the elements within 
the instrument due to the presence of such contaminants would also affect the performance of the 
instrument.  The internal components should be thoroughly cleaned with a volatile solvent, such 
as methanol, to combat this problem.  Software discrepancies may also contribute to the 
irregularity of generated data, in the computation of m/z values or the production of spectra, but 
it is difficult to pinpoint this as a problem unless the entire software were replaced, and data 
generated from the new software is tested.   
 In the cases where no identifications were made for digest spectra of good quality, it is 
always possible that the proteins were as yet uncharacterized/unidentified proteins, not in the 
database.  However, this is unlikely, because the protein bands chosen were intense, they should 
be highly abundant and identified proteins in SM tissue.   
In many digest spectra, what appeared to be contaminating polymer peaks were observed 
(Figures 75- 78).  An experimental blank tryptic digest was performed on a small quantity of the 
latex gloves used regularly in the laboratory.  The resultant spectrum is shown in figure 80.  This 
may explain the source of the contaminating polymer peaks   
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Figure 75:  Tryptic digest averaged spectrum of protein band 6C from the 2D gel 2D_7_30_02_Control, revealing 
contaminating polymer peaks. 
 
Figure 76:  Tryptic digest averaged spectrum of protein band 1C from the 2D gel 2D_7_30_02_Control, revealing 
contaminating polymer peaks. 
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Figure 77:  Tryptic digest averaged spectrum of protein band 23C from the 2D gel 2D_10_09_02_Control, 
revealing contaminating polymer peaks. 
 
 
Figure78:  Tryptic digest averaged spectrum of obtained when trypsin was added to a piece of the latex glove used 
in the laboratory,  The spectrum reveals polymer peaks similar to those seen as contamination in many of the sample 
spectra, and may explain the source of such contamination.  
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 Some observed phenomenon have yet to be explained.  The modified and purified trypsin 
enzyme used for this analysis was purchased from Sigma-Aldrich.  The trypsin was reportedly 
modified by dimethylation of lysine residues to prevent autolysis.  The m/z peaks that would be 
obtained form autolysis of the modified trypsin are listed in table 6.  An experimental blank was 
performed in which the trypsin was incubated with a blank piece of gel in attempt to allow 
autolysis.  The spectra and peak list obtained from this blank may be seen in Figure 79 and Table 
7, below.   
The two sets of peaks for the theoretical and the experimental are incongruent with each 
other.  The explanation for this is not known.  It is suggested that the Sigma-Aldrich trypsin is 
modified in a different way or that instrument was malfunctioning as discussed earlier to produce 
m/z peaks of inaccurate value.  The experimental blank was used to identify contaminating 
trypsin peaks in sample spectra.   
 
 
 
1045.811   1744.266  
1109.803   1849.249  
1158.915   1888.293  
1186.905   1893.404  
1192.941   2048.456  
1236.931   2055.453  
1344.150   2067.366  
1388.186   2209.504  
1432.334   2224.469  
1448.133   2237.546  
1476.169   2351.598  
1492.146   2510.736  
1503.106   2633.923  
1517.081    
1606.148    
1622.192    
1628.224  
1635.198  
1740.406 
 
Table 6:  List of m/z peaks obtained from a theoretical digest of dimethylated trypsin. 
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Figure 79:  Averaged digest spectrum of self-digested, dimethlyated trypsin purchased from Sigma-Aldrich 
performed in the laboratory at Marshall University to be referenced as an experimental blank for identification of 
contaminating trypsin peaks in sample spectra. 
 
 
 
 
 
805.41  1999.04  2580.28 
906.51  2027.08  2586.39 
934.54  2055.11  2803.42 
962.57  2083.14  2831.45 
1020.20  2163.05  2910.31 
1046.60  2191.08  2938.35   
1048.54  2193.99  2966.38 
1048.54  2209.98  3195.48   
1074.63  2238.02  3211.47   
1111.56  2273.16  3223.51 
1139.57  2289.15  3239.50 
1181.61  2301.19  3251.54 
1364.69  2317.18  3267.53   
1392.72  2321.20  3338.64 
1420.75  2349.23  3366.67 
1433.72  2377.27  3670.59 
1461.75  2405.30  3686.58 
1495.61  2514.33  3686.80 
1497.76  2530.33  3698.62 
1523.64  2542.37  3714.61 
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1525.79  2552.24  3714.83 
1725.87  2558.36  3726.65 
1753.89  2570.40  3742.64 
 
 
Table 7:  List of m/z peaks obtained from experimental autolysis of the dimethylated trypsin purchased from 
Sigma-Aldrich.  These peaks are incongruent with those expected from the theoretical digest in table 5. 
 
In many digest spectra, trypsin peaks were evident.  This may be due to a concentration 
of trypsin that was too high for the amount of protein.  Either the quantity of protein in the 
digested band was too low, as was often the case when the gels had to be silver stained, or too 
much trypsin was added.  The abundance of trypsin peaks present in a sample spectrum could 
conceivably suppress actual peptide peaks, making protein identification and other analysis more 
difficult.   
 
PSD Analysis 
 
 It was hoped that the employment of post source decay (PSD) analysis of peptide 
fragments within digested spectra would help facilitate a more positive identification of putative 
proteins.   However, a good PSD spectrum was never obtained using the techniques described in 
this research.  Preliminary spectra obtained in the acquisition of data during the stepwise voltage 
acclamations were of very poor resolution, especially those obtained from low reflector voltages 
which would deflect those fragments of lower MW.  Naturally, if these are of poor quality, the 
subsequent fragmentation spectrum constructed from them will be of equally poor quality.   
Manipulation of lens voltages to improve resolution of peaks proved unsuccessful.  
Because a good standard PSD fragmentation spectrum was never obtained, calibration of the 
instrument could not be performed, much less PSD analysis for an unknown sample spectrum.  
The instrumental software’s peak picking parameters were found to be inadequate for choosing 
real m/z peaks, or else the calibration file was inaccurate.  The m/z peaks chosen by the software 
were not real peaks, but noise spikes.  Definite m/z peaks, though of poor resolution, were 
ignored by the software.  It is probable that the ion gate that functions to preselect the peptide to 
be fragmented from the mixture of analytes was not working properly.  This would inevitably 
cause difficulties in obtaining sufficient PSD data for sequencing the peptide.   
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MASCOT Search Results 
 
 Unfortunately, many protein candidates were found for each peptide fingerprint entered 
into the protein database search—too many to report at full length in this collection.   
An example of the possible candidates for one such spectra—band 1P from the 2D gel 
7_12_02_phorbol_sup—is reported here (Figure 80).  First, a list of the possible candidates was 
obtained from the MASCOT search engine, allowing for the indicated variable modifications.  
These candidates are listed in table 8, below.   
 
 
Figure 80:  Tryptic digest spectra band 1P after from the 2D gel 2D_7_12_02_Phorbol.  The peak list from this 
spectra was searched in the protein database by MASCOT to determine its identification. 
 
 
 
 
 
 
Possible IDs of Band 1P 
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Possible 
Candidates 
# of 
Matching 
Peaks 
MASCOT 
Score 
Sequence 
coverage 
Mass (Da) Variable 
Modifications
α-actinin 30 28 48% 105176 Oxidized Met 
Filamin C 29 42 34% 119496 Oxidized Met 
Plectin 1 32 30 43% 95964  Oxidized Met 
Vimentin 28 35 57% 53623 Oxidized Met 
Vinculin 38 28 41% 117171 Oxidized Met 
Integrin-
linked PK 
31 27 56% 51827 Oxidized Met 
Phos. Thr/Ser 
PKA 26 25 47% 30322 Oxidized Met 
Phos. Thr/Ser 
Table 8:  List of the possible candidates for the identity of band 1P from the 2D gel 7_12_02_phorbol_sup. 
 
Much information can be interpreted using the information in the database, and 
comparisons can be made between the characteristics of likely candidates and the experimentally 
determined parameters of a given protein digest, such as MW and pI.  If these parameters do not 
match that of the unknown, it can be eliminated as a candidate.   The protein α-actinin is used as 
an example to show the comparison.  In figure 81, the sequence of the protein covered by the 
peptide fingerprint spectra is shown.  Table 9 compares the matching peaks in the sample spectra 
to the peptide fingerprint of the protein, α-actinin.   
1    MVMEKPSPLL VGREFVRQYY TLLNQAPDML HRFYGKNSSY AHGGLDSNGK  
51  PADAVYGQKE IHRKVMSQNF TNCHTKIRHV DAHATLNDGV VQVMGLLSN  
101 NNQALRRFMQ TFVLAPEGSV ANKFYVHNDI FRYQDEVFGG FVTEPQEESE  
151 EEVEEPEERQ QTPEVVPDDS GTFYDQTVSN DLEEHLEEPV VEPEPEPEPE 
201 PEPEPVSDIQ EDKPEAALEE AAPDDVQKST SPAPADVAPA QEDLRTFSWA  
251 SVTSKNLPPS GAVPVTGTPP HVVKVPASQP RPESKPDSQI PPQRPQRDQR  
301 VREQRINIPP QRGPRPIREA GEPGDVEPRR MVRHPDSHQL FIGNLPHEVD  
351 KSELKDFFQN FGNVVELRIN SGGKLPNFGF VVFDDSEPVQ KVLSNRPIMF  
401 RGAVRLNVEE KKTRAAREGD RRDNRLRGPG GPRGGPSGGM GPPRGGMVQ  
451 KPGFGVGRGI TTPRQ  
 
Figure 81:  Sequence coverage of the peptides matched for the band 1P from the 2D gel 7_12_02_phorbol_sup to 
α-actinin, obtained from the MASCOT database search.  Matching peptides are shown in red.   
 
1P 
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Amino acid 
Start - End 
Observed 
M+ Ion 
Mass 
(expt) (Da) 
Mass 
(calc) (Da) 
Deviation 
(Da) 
# of 
Missed 
Cleavages 
Amino acid Sequence 
41 - 50 1201.85  1200.84 1198.62 2.22 0 DLLLDPAWEK 
51 - 65 1934.23 1933.22 1931.95 1.27 2 QQRKTFTAWCNSHLR 
54 - 66 1647.73 1646.72 1647.83 -1.11 2 KTFTAWCNSHLRK 
66 - 83 2047.83 2046.82 2048.02 -1.19 2 KAGTQIENIDEDFRDGL
K 
80 - 101 2524.39 2523.38 2521.43 1.95 2 DGLKLMLLLEVISGERL
PKPER Oxidation (M) 
109 - 125 1830.77 1829.76 1830.04 -0.27 2 INNVNKALDFIASKGVK 
115 - 125 1150.06 1149.06 1147.66 1.40 1 ALDFIASKGVK 
182 - 214 3974.08 3973.07 3973.05 0.02 2 NVNVQNFHISWKDGLA
FNALIHRHRPELIEYDK 
205 - 214 1299.32 1298.31 1298.66 -0.35 0 HRPELIEYDK 
218 - 233 1776.38 1775.37 1774.84 0.54 0 DDPVTNLNNAFEVAEK 
234 - 255 2533.84 2532.83 2531.26 1.58 1 YLDIPKMLDAEDIVNTG
RPDEK 
234 - 255 2548.56 2547.55 2547.25 0.30 1 YLDIPKMLDAEDIVNTG
RPDEK Oxidation (M) 
240 - 255 1802.60 1801.59 1801.85 -0.26 0 MLDAEDIVNTGRPDEK 
256 - 283 3120.72 3119.71 3121.51 -1.80 2 AIMTYVSSFYHAFSGAQ
KAETAANRICK 
312 - 331 2485.06 2484.05 2483.28 0.77 2 TIPWLEDRVPQKTIQEM
QQK Oxidation (M) 
332 - 340 1272.09 1271.08 1268.63 2.46 2 LEDFRDYRR 
364 - 378 1730.18 1729.18 1729.90 -0.72 1 LRLSNRPAFMPSEGR 
396 - 410 1915.20 1914.19 1915.98 -1.79 1 GYEEWLLNEIPRLER 
451 - 469 2206.65 2205.64 2206.12 -0.48 2 ALIRKHEAFESDLAAHQ
DR 
519 - 536 2215.74 2214.73 2214.16 0.57 2 TEKQLETIDQLHLEYAK
R 
605 - 632 3141.80 3140.79 3140.69 0.11 2 LSGSNPYTSVTPQIINSK
WEKVQQLVPK 
633 - 643 1327.51 1326.50 1324.67 1.83 1 RDHALLEEQSK 
634 - 643 1171.73 1170.72 1168.57 2.15 0 DHALLEEQSK 
653 - 668 1820.56 1819.55 1820.89 -1.34 0 QFASQANMVGPWIQTK 
Oxidation (M) 
761 - 779 2314.84 2313.83 2314.04 -0.21 1 GISQEQMQEFRASFNHF
DK Oxidation (M) 
780 - 813 3764.53  3763.52 3764.71 -1.19 2 DHGGALGPEEFKGCLIS
LGYDVENDRQGDAEFN
R 
814 - 837 2682.21 2681.20 2682.32 -1.12 0 IMSVVDPNHSGLVTFQA
FIDFMSK 
854 - 868 1706.05 1705.04 1702.93 2.12 1 VLAGDKNFITVEELR 
869 - 882 1689.00  1687.99 1688.82 -0.83 1 KELPPDQAEYCIAR 
900 - 911 1291.10 1290.09 1288.58 1.51 0 SFSTALYGESDL 
Table  9:  List of the matching monoisotopic m/z peaks of the sample band 1P from the 2D 
gel7_12_02_phorbol_sup compared to those of the candidate α-actinin. 
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Variable phosphorylation of serine and threonine residues can also be tested in the 
database search.  However, this comparison allows all possible serine and threonine residues to 
be phosphorylated, when matching theoretical peak masses.  Phosphorylation at so many 
residues at once, or at all, is not likely.  That makes this option of identifying phosphorylation 
sites tedious and most likely inaccurate.  This option also provides more possible candidates for 
identification.   
Only those candidates with significant MASCOT scores (>62) have been reported in 
depth.  It was decided that a definitive positive identification should be concluded before time is 
spent, and likely wasted, investigating every possibility.  Often, many likely candidates were 
produced with comparable, though insignificant, scores.  There is simply not enough evidence to 
choose one candidate over another.  The successfully identified proteins have been discussed, 
previously.   
Only the MASCOT score, percentage of sequence coverage, and number of matched m/z 
peaks for each candidate are reported here.  Of course, some spectra were very poor and did not 
have enough peaks to make any kind of characterization possible.  Spectra with fewer than 8 
peaks were not searched in the MASCOT database.   
 
Unmatched Peaks 
1143.59 1792.38 
1309.17 1841.76 
1313.44 1871.28 
1444.90 1886.98 
1489.97 1901.13 
1551.34 1984.40 
1596.36 2220.76 
1618.66 2234.84 
1715.49 2476.17 
1722.11 2540.46 
1758.34 2576.72 
 
Table 10:  List of the unmatched monoisotopic m/z peaks of the sample band 1P from the 2D gel 
7_12_02_phorbol_sup when compared to the m/z peaks of α-actinin. 
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Unmatched peaks may be molecules with salt adherents—such  as sodium (Na+) or 
potassium (K+)—, matrix peaks, trypsin peaks, or modified peaks (phosphorylated, glycosylated, 
etc).  There is always the possibility that an incorrect identification has been made by the search 
engine.  This probability is too high for candidates with MASCOT scores below the level of 
significance.  Unmatched peaks may even be part of a second protein that migrated to a position 
on the gel near the band of interest, thus contaminating the sample analyte.  Though this does not 
occur very often given the size of normal 2D gels.   
Despite the limitations afforded by poor spectra, some general conclusions can be drawn 
from the lists of possible candidates.  For example, it appears that the protein of band 1P, above, 
is at least a structural or filamentous protein involved in the cytoskeleton, because the majority 
of the likely candidates are structural proteins found in muscle tissue.  The most rational options 
would be either vimentin or α-actinin—structural proteins already known to exist in SM tissue.  
However, the possibility that the protein is an unknown structural protein still remains and 
cannot be ruled out.   
Similar results were found for most of the protein spectra analyzed.  Unfortunately, poor 
spectra prevented a positive identification for most of the spectra analyzed.  Low MASCOT 
scores and a broad range of putative proteins inhibited any successful characterization.  Such 
problems encountered in the development of this research have slowed its progress. 
 
 
Phosphoproteomic Analysis 
 
 Phosphoproteomic analysis was difficult given the methods use thus far and 
incorporating the setbacks imposed by encountered difficulties with the protocol.  Sample 
enrichment, β-elmination, and other specific phosphoproteomic techniques have yet to be 
conducted, and should be attempted in the future.  As mentioned in the introduction, analysis of 
phosphoproteins/peptides is more difficult because of their low stochiometric abundance in 
digested peptide mixtures.  Sample enrichment should improve their selective abundance.  
Phosphopeptides are also very hydrophilic and will not be selectively detained using the standard 
reverse-phase chromatography techniques used in this investigation.  Purification of enriched 
sample using OligoR3 columns should instead by conducted in future work.   
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 Two methods of detecting phosphorylated proteins were attempted in this research.  The 
first utilized radioactive phosphorous-33 (33P) enrichment of tissue extracts coupled with 
autoradiographic detection to assay differential phosphorylation of proteins separated on 2D 
gels.  This method was only attempted once with limited success.  The autoradiographs produced 
from this protocol are shown in figures 82-85.   
 
 
Autoradiograph Control 
 
Figure 82: Autoradiograph obtained from a 2D gel produced from tube gel IEF separation with 12 hours of 
exposure.  Aqueous proteins from resting SM tissue were used.  The radiograph reveals no phosphorylated bands. 
 
 
 
 
 
 
 
 
 
Autoradiograph Phorbol 
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Figure 83: Autoradiograph obtained from a 2D gel produced from tube gel IEF separation with 12 hours of 
exposure.  Aqueous proteins from phorbol-contracted SM tissue were used.  The radiograph reveals 
phosphorylation on the band corresponding to tropomyosin. 
 
 
 
Autoradiograph Phorbol 
 
Figure 84: Autoradiograph obtained from a 2D gel produced from tube gel IEF separation with 36 hours of 
exposure.  Aqueous proteins from phorbol-contracted SM tissue were used.  More evidence of phosphorylated 
bands can be seen.  
 
 
Autoradiograph Phorbol-Membrane Proteins 
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Figure 85: Autoradiograph obtained from a 2D gel produced from tube gel IEF separation with 36 hours of 
exposure.  SDS-solubillized proteins from phorbol-contracted SM tissue were used.  More evidence of 
phosphorylated bands can be seen. 
 
 
For the first trial, evidence of phosphorylated proteins can be seen only for the protein 
band corresponding to tropomyosin on the phorbol-contracted gels (Figure 82).  So, it can be 
concluded that the level of phosphorylation of tropomyosin increases during contraction.  The 
enzyme that phosphorylates/dephosphorylates this protein is not known.  This method was used 
in conjunction with tube gel IEF focusing.  For this reason, the quantity of protein on the gel 
available for detection and subsequent analysis is low, as expected.  The gels had to be silver 
stained to visualize any protein bands.  This may explain the lack of evidence of phosphorylated 
proteins on the gel.    
For the second trial, only gels corresponding to phorbol-contracted tissue were obtained. 
The corresponding silver stained gels can be seen in figures 32 and 46, respectively.  These 
autoradioagraphs were subjected to a longer exposure time, so that phosphoprotein bands were 
more intense and better visualized.  However, due to the lack of a corresponding control gel for 
resting tissue, differential analysis could not be conducted at this point.  No protein 
identifications were made from these gels for the reasons discussed previously.  Mainly, low 
protein concentration in the bands visualized by silver staining made analysis difficult, and thus 
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far, unsuccessful.  Therefore, the identity of the phosphoproteins visualized on these gels is not 
known.  However, improvement in this area promises better analysis for the future.   
The second method for visualizing phosphoproteins makes use of the phosphospecific 
stain from Molecular Probes—ProQ Diamond Phosphoprotein stain, which binds more tightly to 
phosphorylated proteins than nonphosphorylated proteins due to charge interactions between the 
negatively-charged phosphate groups and the positively-charged stain molecules.   
No bands were ever visualized using this stain, despite attempted modifications of 
lengthened staining and destaining periods.  This method was attempted only in connection with 
the gels produced from IPG strips, so the total protein concentration should be high enough for 
detection.  It is possible that the light source and camera used to excite and detect the stain were 
insufficient.  The appropriate camera and filters may greatly enhance the sensitivity of the stain.  
These resources were not available.  It is also possible that the stain is simply not sensitive 
enough to bind to and detect the low abundant phosphoproteins in biological samples.   
Interference between the stain and free phosphate groups can occur if tissues are 
incubated in phosphate buffers.  No such buffers were used during the lysis procedure conducted 
in preparation of the sample.  Protein extracts should also be sufficiently purified during the 
acetone precipitation.   
Because phosphoproteins were not sufficiently detected using the phosphoprotein stain, 
gels were stained with a total protein stain to look for deviations in the intensity of 
corresponding bands between the contracted and uncontracted gels.  However, identification of 
proteins was not achieved, as was discussed earlier.   
 
 
 
 
 
 
 
 
 
CONCLUSIONS 
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Though some identifications of proteins in SM have been made given the results, thus 
far.  Unexpected setbacks and other protocol adaptations have slowed research.  So far, the 
localization of actin, tropomyosin, and MHC on a 2D gel has been discovered.  It has also been 
concluded that tropomyosin is phosphorylated during contraction.  As tropomyosin and actin 
bands can be seen in almost every gel, it may be concluded that they are present in abundance 
within aortic SM tissue. The heavy phosophorylation of this abundant protein implicate that this 
protein may play a larger role in contractile regulation than originally thought.  
The primary objective of this research focused on the differential phosphorylation 
analysis between contracted and resting aortic SM tissue in order to better understand the 
mechanisms of signal transduction.  Instead, the body of this work focused on the development 
of protocol for the analysis of phosphoproteins.  Many problems were identified and solved.  
However, the largest obstacle of acquiring accurate, reproducible MS data to facilitate 
identification of proteins using the protein database still remains.   
Future work in this investigation should include a Bradford assay for protein quantitation, 
use of the IPG strips for IEF separation of proteins to improve protein concentration on the 2D 
slab gels, and the use of phosphoproteomic techniques (sample enrichment of phosphoproteins, 
phosphatase inhibitors in cell lysis, ß-elimination, Michael addition, etc.) for the selective 
analysis of phosphoproeins.  Analysis of differential glycosylation in control and contracted SM 
tissue may be of interest for the future, as well.   
Once a suitable protocol has been developed, the use of proteomic analysis should 
provide valuable information concerning the phosphorylation state of proteins in SM due to 
contraction, and from this information, conclusions made be drawn about signal transduction 
behind it.  Once such goals have been accomplished, it should be followed by the use of different 
states of contraction (tonic/phasic), time dependent exposure of tissue to agonist, the effects of 
different agonists and/or relaxants on the state of phosphorylation, and perhaps different SM 
tissues.  Ofcourse, analysis of signaling cascades in dysfunctional SM tissue should be explored, 
as well.  There are many avenues of exploration that may be pursued, both biochemical at the 
molecular level and biophysical at the macroscopic level—mechanics/dynamics of contraction.   
These preliminary results are just a small step in the process of understanding SM 
contraction.  The need for its understanding becomes evident when the dominant and ever-
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expanding threat of cardiovascular disease—the second leading cause of death in the United 
States, and number one in many countries (AHA 2002)—is considered.  A thorough 
understanding of contraction in normal tissue will provide the base for which dysfunctions can 
be compared.  Drug therapy, in particular, calls for the development of new, improved relaxants 
for the treatment of hypertension.  Vascular SM contraction may also play a role in the 
development of atherosclerosis, which may be treated within SM tissue.  Improvements in 
phosphoproteomic techniques and instrumentation capabilities will aid in the conquest.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX I: 
Mass Spectrometry 
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The general principle behind mass spectrometry (MS) is the separation of gas phase ions 
based on their molecular weight (MW), or more specifically, the ratio of their mass to charge 
(m/z).  The advanced technology and specialization of mass spectrometry instrumentation and 
applications grows increasingly complex and sophisticated.  Therefore, this appendix will cover 
only the general characteristics of MS.   
The instrumentation of a mass spectrometer operates under three basic components:  the 
source, the mass analyzer, and the detector.  The choice of which type of each component is used 
depends on their suitability to the most desired qualities for sample analysis. 
The source serves to vaporize and ionize—supple an electrical charge to—the sample 
analyte.  Several different methods of ionization have evolved through avid research.  In general,  
the ionization technique must transfer enough energy to the sample to cause it to vaporize.   
 In electron ionization (IE), the sample is bombarded with thermionic emission from a 
tungsten or rhenium filament (typically 70 eV).  Fast atom bombardment (FAB) blasts a matrix-
embedded sample with a fast beam of particles—usually an inert gas (Ar/Xe)—to facilitate 
ionization.  Similarly, liquid secondary ion mass spectrometry (LSI-MS) uses an ion (usually 
CS+) to ionize the sample.   
In electrospray ionization (ESI) makes use of the phenomenon of charged droplet 
evaporation.  The sample solution is forced through a capillary to cause spraying or bubbling, 
producing minuscule charged droplets.  A potential is then used to disperse the droplet into a fine 
spray of smaller droplets.  The solvent evaporates away, shrinking the droplet, and causing the 
charged ions to get closer and closer together, until Coulombic repulsion causes the droplet to 
explode into smaller droplets.  The process repeats itself until naked analytes are accomplished.  
The only problem with this technique lies in the statistical probability that analytes will be 
multiply-charged, which is not always desired.  Smaller capillaries and slower flow rates 
decrease this probability, and, therefore, increase m/z ratios. 
Matrix-assisted laser desorption/ionization (MALDI) couples a LASER pulse with a 
suitable matrix-embedded sample to produce molecular ions.  The sample is embedded 
homogeneously in the matrix on a metal probe, facilitated by co-crystalization.  The matrix, a 
small organic molecule, absorbs strongly at the wavelength of the LASER, and must itself be 
sublimable.  It serves to donate its excitation energy to the sample, protects the sample 
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decomposition and/or aggregation of the analyte, and is also thought to donate protons to ionize 
the analyte (Figure 86). 
 
Figure 86:  Illustration of a sample embedded in matrix on a metal probe. 
 
This disadvantage of this technique is that the short duration of the ion burst produced by 
the laser desorption prevents association of the source with quadropole analyzers, but makes it 
ideal for coupling with time of flight (TOF) analysis.  
The mass analyzer is the component that separates the molecular ions.  This can be 
accomplished based on the differential physical properties of the ions, done so in several ways.   
In a double focusing sector mass analyzer, ions are accelerated through a potential into an 
electrostatic analyzer, which focuses ions of the same m/z to the same path, improving 
resolution.  The ions then enter the magnetic sector, which produces a curved magnetic field—
between 60 and 120°—whose strength can be varied to direct the flight path of different m/z ions 
toward the detector. 
A time of flight mass analyzer accelerates molecular ions through a potential, supplying 
them with a characteristic kinetic energy (KE).  The ions are them allowed to fly down a long 
chamber, or flight tube, under vacuum toward the detector.  The ions will fly at a velocity 
characteristic of their KE, and that is a function of their molecular weight. 
      PE = eV = KE = ½ mv2                (2) 
where PE = potential energy (Joules), V = voltage (volts), e = electron volts, m = mass (kg), and 
v = velocity (m/s).   
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 A quadropole mass analyzer is composed of four parallel rods, with static direct current 
(DC) through two, and alternating radio frequency (rF) applied to the other two.  Ions are passed 
through the quad, and only those with the correct m/z values necessary to traject their path 
straight through the poles are detected, while all others deflected.  The mathematics behind the 
physical event are complex, and will not be discussed. 
 In fourier transform ion cyclotron resonance (FT-ICR)—often referred to as FT-MS—, 
ions are first focused into a vacuum chamber.  They then enter a cell housing a static magnetic 
field (B field), which causes the charged moieties to rotate in a circular orbit perpendicular to the 
field at a velocity characteristic of their m/z, and governed by the Lorentzian force.   
F = zvB            (3) 
where F = Lorentzian force.   
An angular frequency (ω) is obtained because the ion is bent into the circular path. 
ω = zB/2πm            (4) 
Ions are detected when an Rf pulse is used to excite ions at the correct m/z into a larger orbit. 
The passing charge frequency is detected by two detectors located on either side of the cell, and 
a waveform is recorded.  The waveform is computed back to the ion’s m/z.   
 The ion trap is a system of three electrodes in a chamber that use varying voltages and Rf 
to trap ions in (Figure 87).   
 
Figure 87:  Diagram of the ion trap mass analyer. 
The ring electrode produces a three-dimensional electric field which causes ions to stay within 
the cell, with a trajectory dependent on their m/z. 
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 The field is then changed to destabilize the ions’ trajectories, so that the ions are ejected 
from the trap—smallest m/z to largest.  
 The third component is the detector which receives and processes the m/z signal.  The 
detector transforms the electrical signal into a digital mass spectra, which is a plot of the ion 
intensity verses the m/z value. 
 Briefly, some general phenomenon associated with mass spectra, include the 
manifestation of isotopic peaks of a given ion.  This is caused by the presence of multiple atomic 
isotopes that exist within a molecule, such as a deuterium ion (D) instead of a hydrogen.  In 
peptides/proteins, frequent isotopes of hydrogen, nitrogen, carbon, and sulfur are usually seen.  
In a peptide spectra    (<5000 Daltons (Da)), the result is a collection of peaks at the m/z, the first 
peak being the most abundant monoisotopic peak, except at higher mass values, where the 
probability of having to higher mass isotope atoms among the population of atoms increases.  In 
a protein peak, isotope peaks are not clearly defined, but overlap each other (Figure 88). 
 
 
Figure 88:  Illustration of a general peptide and protein mass spectrum, revealing the phenomenon of isotopic 
peaks.   
 
Either the monoisotopic peak m/z can be used for analysis, or an average of the isotopic peaks 
can be used to characterize the molecular ion.   
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 In biological samples, another frequently observed phenomenon is evidence of dimers, 
where two homogeneous or heterogeneous molecules are associated with each other and 
manifested in the same m/z peak.  In the case of a homogeneous dimer, the m/z peak would 
appear at twice the normal mass [M+] of the protein.  A molecular ion can also be doubly-
charged [M2+], which would result in an m/z peak at half the normal mass value (Figure 89). 
 
Figure 89:  Simplified illustration showing the existence of a dimer peak and a doubly-charged peak [M2+] in the 
same spectra as the normal molecular ion [M+].   
 
  
Applications of MS are numerous and exist in research, testing, and development practices of 
many areas; including industry, pharmaceuticals, academia, government, forensics and more.  It 
is probably the most useful and widely-used technique, today.  Advancements of instrumentation 
design continue to shape its influence and applicability in the progression of science.   
 
 
 
 
 
 
 
 
APPENDIX II: 
MALDI-TOF MS and PSD 
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  MALDI-TOF MS uses a soft ionization technique coupled to a time of flight analyzer to 
provide quick m/z analysis of broad mass ranges with high sensitivity (see Appendix I).  This 
method can detect picomolar (pm) quanities of analyte, and there is virtually no upper mass limit 
of detection.   
For this research, a Bruker Biflex III MALDI-TOF was used.  The Bruker Biflex III uses 
a nitrogen LASER source of 337.1 nm wavelength and 0.1 nm spectral bandwidth.  The matrices 
used with this laser are sinapinic acid for proteins and α-cyano-4-hydroxycinnamic acid (HCCA) 
for peptides (Table 11). 
 
 Other names Use Structure 
α-cyano-4-
hydroxycinnamic 
acid 
HCCA, α-cyano Peptides 
sinapinic acid 3,5-Dimethoxy-4-
hydroxycinnamic 
acid 
 
Proteins 
 
Table 11:  Matrices coupled with the nitrogen laser source for the Bruker Biflex III MALDI-TOF MS. 
 
  After desorption, ions are accelerated by a potential energy (PE) of 19 kV, which gives 
them a kinetic energy (KE), (equation 1).  Ions are then allowed to travel down the time of flight 
tube at a velocity (v) that is characteristic of their mass (m). 
 117
PE = eV = KE = ½ mv2              (5) 
where V = volts, e = electron volts.  Smaller mass particles will travel faster and arrive at the 
detector first.  Mass to charge (m/z) values are computed based on the particles time of flight 
after acceleration (equation 2).   
TOF = L  × √(m/z)/2Ve             (6) 
where L = length of flight tube. 
 The instrument can activate in either positive or negative ion mode.  Positive ion mode 
accelerates postively-charged ions toward the detector using a negative PE.  Negative ion mode 
uses a positive voltage to accelerate negative ions.  
 The Bruker Biflex III design offers a delayed extraction function in which desorped and 
ionized particles are caught and focused by a set of focusing voltages/lenses (Figure 90).  When 
the ions are blasted off the metal probe, they receive a KE.  Each ion may have a different initial 
KE and starting position within the ionization chamber/source from which they may be 
accelerated (Figure 91).    
 
 
Figure 90:   Diagram of the source (ionization chamber) and TOF tube of the Bruker Biflex III MALDI-TOF MS.  
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Figure 91:  Illustration of the different starting positions of molecular ions in the ionization chamber prior 
to acceleration. 
 
This will affect their time at which they will arrive at the detector and can cause 
broadening of peaks/loss of resolution.  The focusing lenses help to equilibrate and concentrate 
the particles before they are accelerated by the 19 kV. 
 The Biflex III also offers a reflectron mode to further improve resolution and to allow 
post source decay (PSD) analysis.  At the end of the flight tube are a series of reflector voltages 
which deflect oncoming particles back towards a detector at the other end of the tube, supplying 
a longer flight path and improved separation of ions (Figure 92).  Reflectron mode is normally 
used for the analysis of peptides ( <5000 Da).  Linear mode is normally used for proteins.  
 
 
Figure 92:   Diagram of the path of ions after reflection due to the reflector voltages in reflectron mode of the 
MALDI-TOF. 
 119
 The reflectron feature also facilitates PSD, which can be used to devise structural 
information.  A higher LASER power is used to supply more internal energy to the matrix and 
analyte.  An ion gate (voltage) is used to select the molecular ion (m/z value) to be fragmented 
for PSD analysis.  PSD theory makes use of the characteristic fragmentation of metastable 
molecular ions that occurs because of high internal energy and collisions that occur between the 
analyte, matrix ions, and/or residual gas in the flight tube (Kaufmann 1993).  The molecular ion 
achieves its characteristic KE, and then fragments.  The fragments will all have the same 
velocity, but the KE will be divided among the fragments (equation 3). 
KE = ½ m1v2 + ½ m2v2 + ½ m3v2 + etc.            (7)  
The technique uses stepwise decreases in reflector voltages, collecting spectra at each voltage.  
Each reflector voltage focuses and deflects ions within a small KE range.  This is known as a KE 
filter.  High mass fragments are deflected first, and then increasingly lower mass fragments are 
deflected at each voltage.  All the spectra are then computed and calibrated into a final 
fragmentation spectrum.  Several properties such as LASER attenuation, focusing lens voltages, 
and reflector voltages can be adjusted to provide optimal resolution when collecting a spectrum.   
A PSD spectrum reveals broken pieces of a peptide that can be put back together like a 
puzzle to reveal connectivity of composite amino acids. This can be used to devise structural 
information because fragmentation occurs along the weakest bond.  In protein samples, this is 
usually the peptide bond (Figure 93). 
 
 
Figure 93:  Illustration of the fragmentation of a peptide bond during PSD analysis.    
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Some limitations of PSD are that it is time-consuming to collect a spectrum at each 
reflector voltage, and then paste the spectra together.  The technique is also less sensitive 
because it requires an increased amount of sample.  A sample is depleted as a spectrum has to be 
collected at each voltage.  There is also a loss of resolution associated with PSD that the reflector 
voltage normally supplies in normal analysis of peptides.   
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Appendix III: 
 
General Steps Involved in Proteomic Analysis of Biological Samples 
 
1.  Isolation of Proteins 
Isolation is usually facilitated by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis), in either one (1D) or two dimensions (2D).  1D electrophoresis separates a 
solubilized mixture of proteins by their molecular weight (MW), only.  2D electrophoresis also 
separates protein fractions by their isoelectric point (pI) in a pH gradient strip or gel.  Isolation 
can also be accomplished by chromatography, in which various affinity reactions selectively 
retain desired products through antibody binding, enzyme-substrate association, or other specific 
chemical reactions (phosphorylation, glucosylation).  A less efficient separation can be 
accomplished by centrifugation. 
 
2. Purification  
Purification of samples can be achieved by dialysis prior to or after electrophoresis to 
filter lower MW contaminates such as salts from buffers or detergents, etc through a porous 
membrane in solution.  Reverse-phase HPLC (high pressure liquid chromatography) or Ziptip 
concentration and desalting may be applied to protein/peptide mixtures, as well.  In these 
methods, proteins or peptides mixtures are passed through and retained by tightly-packed 
columns of hydrophobic resin.  They are then eluted off the column with a hydrophobic solvent, 
such as acetonitrile.   
 
3.  Analysis  
Analysis is usually performed using some form of mass spectrometry (MS), (see 
appendix I).  Information that can be obtained by MS includes 1) MW, 2) amino acid (aa) 
sequence of peptides/proteins, 3) detection of post-translational modifications (phosphorylation 
sites, glucosylation sites), 4) detection of mutations, 5) isotopic abundance, 6) fragmentation 
patterns revealing structural information, 7) peptide fingerprints of proteolytically digested 
proteins, and 8) identification of unknown proteins when coupled with peptide maps in protein 
databases (facilitated to a large degree by the HGP).   
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APPENDIX IV: 
Important Proteins in Smooth Muscle 
 
Protein  MW (Da) Theor- 
etical pI 
Function Known P-
Sites 
α-Actin  41,747 5.24 Composition of thin 
filaments. 
UNKNOWN 
Myosin Heavy 
Chain (MHC)–
SM1A fragment 
79,985 Undefined Fragment of MHC that 
makes up the thick filaments. 
UNKNOWN 
MHC—SM1B 
fragment 
80,736 Undefined Fragment of MHC that make 
up the thick filaments. 
UNKNOWN 
Myosin essential 
light chain 
(MLCessential) 
16,843.9 4.46 Part of the myosin head. UNKNOWN 
Myosin regulatory 
light chain (MLC-
20) 
19,764.1 4.67 Part of the myosin head. 
Regulates activity of 
actomyosin motor. 
Thr-18 
Ser-19 
Heavy 
meromyosin 
(HMM) 
------------ ------------
------- 
Fragment of myosin formed 
by trypsin digestion—hinge 
region and ATPase. 
UNKNOWN 
Light meromyosin 
(LMM) 
------------
- 
------------
------- 
Fragment of myosin formed 
during trypsin digestion—
associates w/ other LMM to 
form filament. 
UNKNOWN 
Tropomyosin (Tm) 32,957.7 4.63 Thin-filament-associated 
protein-may help regulate 
contraction. 
UNKNOWN 
Myosin light chain 
kinase (MLCK) 
113,993 5.48 Induces contraction by 
phosphorylating MLC-20. 
UNKNOWN 
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Myosin light chain 
phophatase 
(MLCP)—cardiac 
isoform 
26,262 5.78 Inhibits contraction by 
dephosphorylating MLC-20. 
UNKNOWN 
MYPT1—MLCP 
subunit 
8812 Undefined Subunit of MLCP that targets 
myosin.   
 
UNKNOWN 
PP1C—MLCP 
subunit 
36,983  6.12 Catalytic subunit of MLCP 
that dephosphorylates MLC-
20 
UNKNOWN 
20 kDa Fragment ~20, 000 Undefined Subunit of MLCP.  Unknown 
function 
UNKNOWN 
Tropomyosin (Tm) 32,138.99 4.90 Associated with actin thin 
filaments.  May help regulate 
contraction. 
UNKNOWN 
Calmodulin (CaM) 16,706.3 4.09 Binds Ca2+ after influx; 
combines with MLCK to 
activate it.  
Thr-44 
α-Actinin 103,653.5 5.36 Found in the dense bodies of 
SM, analogous to z-discs in 
skeletal muscle—serve as 
attachments points for actin 
filaments. 
UNKNOWN 
Desmin 53,366.6 5.21 Found in the intermediate 
filaments of SM. 
UNKNOWN 
Vimentin 53,524.0 5.06 Found in the intermediate 
filaments of SM. 
Ser-38 
Ser-82 
Smoothelin 100,135 9.01 Filamentous structural 
calponin-like protein present 
in the cytoplasm. 
UNKNOWN 
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Calreticulin 46,319.8 4.33 Binds Ca2+ in the SR. UNKNOWN 
Calsequestrin  41,662.9 3.96 Binds Ca2+ in the SR. UNKNOWN 
Phospholamban   SR membrane protein that 
may regulate the Ca2+ pump 
in the SR when 
phosphorylated. 
Ser-16 
Thr-17 
RhoA 21,428.8 5.83 Regulatory protein in 
pathway of agonist-induced 
contraction.  
UNKNOWN 
Rho-associated 
Kinase (ROK) 
159.526.6 5.72 Regulatory protein activated 
by RhoA. (See Appendix 
IIIf) 
UNKNOWN 
cAMP-dependent 
protein kinase 
(PKA) 
40,462.9 8.71 Regulatory kinase activated 
by elevated [cAMP].  (See 
Appendix IIIe) 
Ser-10 
Ser-139 
Ser-338 
Thr-197 
Lys-72 (ATP) 
cGMP-dependent 
protein kinase 
(PKG) 
Undefined Undefined Same as PKA. UNKNOWN 
Protein Kinase C 
(PKC) 
76,742.9 6.61 Regulatory kinase activated 
by IP3.  (See Appendix IIId) 
Thr-638 
Thr-631 
Lys-368 (ATP) 
Phospholipase C-β 
(PLC-β) 
138,257.5 5.86 Cleaves phosphinositol into 
IP3 and DAG.   
Ser-887 
ZIP kinase 51,3891.8 8.91 Phosphorylates MLCP and 
CPI-17.  May be activated by 
ROK.   
UNKNOWN 
Calmodulin kinase 
II (CaM KII) 
60,042.6 6.84 Regulatory kinase activated 
by elevated [Ca2+].  (See 
Lys-42 (ATP) 
 125
Appendices IIIa and IIIb) 
Integrin-linked 
kinase 
51313.9 8.30 Regulatory kinase that 
phosphorylates MLC-20. 
Lys-220 (ATP) 
Mitogen-activated 
protein kinase 
(MAPK) 
42,023.8 8.67 Regulatory kinase in 
contraction.  (See Appendix 
IIIg) 
Thr-180 
Tyr-182 
Lys-54 (ATP) 
Mitogen-activated 
protein kinase 
kinase (MAPKK) 
43,306.3 6.20 Phosphorylates and activates 
MAPK.  
Ser-217 
Ser-221 
Lys-96 (ATP) 
Raf 67,508.37 9.27 Regulatory kinase involved 
in contraction. (See 
Appendix IIIg) 
Lys-334 (ATP) 
Ras 21,300.58 5.16 Regulatory GTPAse protein 
involved in contraction. (See 
Appendix IIIg) 
UNKNOWN 
Phospholipase A2 
(PLA2) 
13665.9 4.88 Calcium-dependent enzyme 
that cleaves arachidonic acid 
(AA) from phospholipids. 
UNKNOWN 
Heat shock protein 
20  (HSP-20) 
17.494.1 6.05 Inactivates the actomyosin 
MgATPase when 
phosphorylated by 
PKA/PKG 
UNKNOWN 
Ryanodine 
receptor (RyaR) 
  Ca2+ ion channel in the SR. 
Allows Ca2+ influx. (See 
Appendix IIIc) 
UNKNOWN 
IP3 receptor Ca2+ 
channel 
Undefined Undefined Ca2+ ion channel in the SR. 
Allows Ca2+ influx. (See 
Appendix IIIc) 
UNKNOWN 
 Ca2+/Na+ 
Exchanger 
Undefined Undefined  Ca2+ ion channel in the 
plasma membrane (PM).  
UNKNOWN 
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Removes Ca2+ from the 
cytosol. (See Appendix IIIc) 
Ca2+-ATPase 
pump 
Undefined  Undefined Ca2+ ion channel in the PM. 
Removes Ca2+ from the 
cytosol. (See Appendix IIIc) 
UNKNOWN 
 
P-Sites = Phosphorylation Sites 
 
Information was obtained from the Swiss-Prot protein database.237 
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APPENDIX V:  
 
20 Common Amino Acids 
 
 
      Name     Abbrev.    Symbol     MW                   pI                        Structure 
 
 
 
1.  Alanine        Ala  A      89.09                 6.00 
 
 
 
 
 
2. Arginine            Arg   R   174.2                  11.15 
  
   
 
 
 
3.  Asparagine        Asn  N           132.12                5.41 
 
 
 
 
 
 
4. Aspartic Acid     Asp  D     133.10       2.77 
 
 
 
 
 
 
5.  Cysteine        Cys  C     121.15        5.02     
 
 
 
 
 
6. Glutamine        Gln  Q      146.15         5.65     
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7. Glutamic Acid    Glu  E       147.13          3.22     
 
 
 
 
 
8. Glycine         Gly  G        75.07           5.97   
 
 
 
 
 
9. Histidine         His  H       155.16                 7.47  
 
 
 
 
 
10. Isoleucine         Ile  I        131.17           5.94  
 
 
 
 
 
11. Leucine        Leu  L        131.17            5.98 
 
 
 
 
 
12. Lysine         Lys  K        146.19  9.59 
 
 
 
 
 
13. Methionine       Met  M        149.21               5.71  
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14. Phenylalanine   Phe  F         165.19  5.41  
 
 
 
15. Proline               Pro           P         115.13  6.30  
 
 
 
 
 
 
16. Serine           Ser  S         105.09            5.68  
 
 
 
 
 
17. Threonine           Thr   T          119.12  5.64  
 
 
 
 
 
18. Tryptophan          Trp   W           204.23            5.89 
 
 
 
 
 
19. Tyrosine            Tyr  Y          181.19             5.66 
 
 
 
 
 
20. Valine           Val   V          117.15             5.96  
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